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Adverse pregnancy outcomes such as preterm delivery, hypertensive disorders of 
pregnancy, small for age neonates and stillbirths are major determinants of perinatal 
mortality and morbidity. As the pathology of these complications of late pregnancy may 
be established in the first half of pregnancy, it seems reasonable to focus on this period 




This thesis focuses on one of the placenta-derived serum markers, pregnancy associated 
plasma protein -A (PAPP-A). It is a well-established biomarker for Down’s syndrome 
screening. The main purpose of this thesis is to conduct a systematic review of the 
literature regarding the association between first trimester serum PAPP-A levels and 
adverse pregnancy outcomes and to investigate the same in a retrospective cohort study 




The systematic review included 32 studies involving a total of 175,240 pregnancies. It 
showed that low maternal serum PAPP-A in the first trimester has an association with 
adverse pregnancy outcome but predictive values are poor. The retrospective cohort 
study of 12,592 pregnancies identified statistically significant lower odds of SGA, PTD, 
PE and stillbirth as PAPP-A increases. There was no statistically significant association 
between miscarriage, perinatal or neonatal death with PAPP-A. 
Further work should address PAPP-A in combination with other predictors as a 










With the increasing understanding of the natural history of diseases down to the 
molecular level, the focus of medicine is gradually shifting from treatment of the 
disease to the prevention of the disease process before it can cause any adverse 
effects. There is emerging evidence that prematurity hinders normal developmental 
maturation of the multiple organ systems causing long term dysfunctions like 
cardiovascular disorders, lung disorders and mental health problems (1). Small for 
gestation age neonate is at higher risk of neurodevelopmental delays (2). 
Hypertensive disorders of pregnancy is a leading cause of maternal and fetal mortality 
and morbidity (3). Hence in obstetrics, this means predicting above mentioned 
adverse pregnancy outcomes (preterm delivery, hypertensive disorders of pregnancy, 
small for gestational age neonates and stillbirths) as these are major determinants of 
perinatal mortality and morbidity. Such prediction would enable us to target 
appropriate surveillance, intervention and possibly treatment at these high-risk 





This thesis focuses on examining one of the placenta-derived serum markers, 
pregnancy associated plasma protein -A (PAPP-A) could predict adverse pregnancy 
outcomes mentioned above. PAPP-A is already a well-established marker for Down’s 
IV  
syndrome screening which is universally offered to all pregnant women in UK. It could 
prove to be a convenient and cost effective biomarker if it could predict adverse 
pregnancy outcomes along with fetal aneuploidy. It could be used in early identification 
of pregnancies at increased risk of subsequent poor outcomes. 
 
This thesis also examines CRL and NT as prognostic indicators for adverse pregnancy 
outcomes. The clinical utilisation of CRL as an individual prognostic factor (i.e. outside 
of a model using it as a continuous factor) is less clear as standard care in the UK is for a 
single first trimester ultrasound to incorporate dating (using CRL) and NT for aneuploidy 
risk. 
 
The aim of this thesis was: 1) To perform a systematic review to assess the predictive 
accuracy of first trimester serum PAPP-A for adverse pregnancy outcomes measured in 
terms of pregnancy loss, preterm birth, intra-uterine death (IUD) and small for gestational 
age (SGA), and hypertensive disorders of pregnancy and 2) To perform a retrospective 
cohort study to assess the predictive accuracy of maternal serum PAPP-A along with 
CRL and NT in first trimester for adverse pregnancy outcome in the population at 





1) Systematic review 
 
a) Search strategy 
 
Medline, Embase and CINAHL (From inception to May 2015) 
 
b) Selection criteria 
V  
 
Studies including pregnant women with PAPP-A in the first trimester and assessment 
of pregnancy outcome. 
c) Data collection and analysis 
 
Data were extracted on study characteristics, quality and results to construct 2x2 
tables. Meta-analysis of odds ratios (OR), sensitivity, specificity and likelihood ratios 
and 95% confidence intervals (CI). 
2) Retrospective cohort study 
 
We investigated association using data on the serum PAPP-A along with CRL and 
NT and pregnancy outcome data Birmingham Women’s NHS Foundation Trust from 





1) Systematic review 
 
Thirty-two studies including 175,240 pregnancies. PAPP-A <5th centile had a moderate 
association with: Birthweight <10th centile OR 2.08 (95% CI 1.89 – 2.29), <5th centile 
OR 2.83 (95% CI 2.52 – 3.18) and <3rd  centile OR 2.76 (95% CI 1.78 – 4.28); pre- 
eclampsia OR 1.94 (95% CI 1.63 – 2.30), preterm birth <37 weeks OR 2.09 (95% CI 
 
1.87 – 2.33), pregnancy loss ≤ 24 weeks OR 2.50 (95% CI 1.81 – 3.47) and stillbirth > 
24 weeks gestation OR 2.40 (95% CI 1.45 – 3.99). For a composite adverse outcome 
OR 3.31 (95% CI 1.80 – 5.11). Where data was available, to look at odds of an 






2) Retrospective cohort study 
 
12,592 pregnancies: 852 (6.8%) pre term birth (PTB), 352 (2.8%) pre-eclampsia (PE), 
 
1824 (14.5%) Small for gestational age (SGA), 73 (0.6%) miscarriages, 37(0.3%) 
 
stillbirths, 73 perinatal deaths (0.6%) and 38 (0.30%) neonatal death (NND). For 
individual prognostic markers in adjusted analyses there were statistically significant 
lower odds of SGA [odds ratio (OR) 0.87 (95% CI 0.85, 0.90)], PTB [OR 0.92 (95%CI 
 
0.90, 0.96)], PE [0.91 (95% CI 0.85, 0.97)] and stillbirth [OR 0.72 (95% CI 0.53, 0.99)] 
 
as PAPP-A increases. There were statistically significant lower odds of SGA [OR 0.80 
(95% CI 0.71, 0.90)], but higher odds of miscarriage [OR 1.75 95% CI (1.12, 2.72)] as 
Nuchal Thickness (NT) increases, and statistically significant lower odds of stillbirth as 
crown rump length (CRL) increases [OR 0.94 95% CI (0.89, 0.99)]. Combining three 
first trimester potential prognostic factors there remains statistically significant 
associations between: a) PAPP-A, NT, CRL and SGA, b) PAPP-A and PTB, c) PAPP- 





Systematic review performed in our study showed that low maternal serum PAPP-A in 
the first trimester has an association with adverse pregnancy outcomes but predictive 
values are poor. The cohort study showed that low PAPP-A is a risk factor for adverse 
pregnancy outcomes, especially SGA.  NT and CRL are potential prognostic factors. 
National guidelines have identified this evidence and have recommended increased 






Perhaps an exclusive national guideline for managing pregnancies with low PAPP-A 
outlining surveillance for adverse outcomes like pre-eclampsia, pre term birth and SGA 
would be useful. Further work is needed to address PAPP-A as a continuous variable 
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Adverse pregnancy outcomes such as stillbirth, preterm birth, intrauterine death 
(IUD), small for gestational age neonate (SGA) and preeclampsia are the major 
determinants of perinatal mortality and morbidity of pregnancy and thus have a major 
psychological impact for the family as well as an increased cost to the health care 
system. However, the conditions often are not detected until the pathological processes 
have become too advanced to facilitate optimal management. Early identification of 
high-risk pregnancies would make it possible to target appropriate surveillance, 
intervention and possibly early treatment at these high-risk pregnancies, hopefully 
before irreversible damage occurs, thereby improving the outcome. At present this 
increased surveillance is offered in pregnancies deemed to be high risk mainly on risk 
factors identified in the past medical or obstetric history rather than the current 
pregnancy.  
 
                      The use of first trimester screening including nuchal translucency (NT), 
pregnancy-associated plasma protein-A (PAPP-A), free-beta subunit human chorionic 
gonadotrophin (fβhCG) to detect aneuploidy has become an integral part of prenatal care. 
There have been numerous studies and reviews reporting the effectiveness of the serum 
PAPP-A to identify pregnancies at high risk for additional adverse perinatal outcomes (5-
9). A review by Halscott et al concluded that the first trimester biomarkers do not have 
sufficiently high enough positive predictive values to be used for first trimester screening for 
the development of preeclampsia, fetal growth restriction, preterm birth or stillbirth (10). There 
are also studies  suggesting there might be no association between serum PAPP-A and 
adverse pregnancy outcomes (11).  
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                       A comprehensive systematic review by Morris et al examined 44 studies including 
169,637 pregnant women concluded that Down’s serum screening analytes including low 
serum PAPP-A have been associated with pre-eclampsia and small for gestational age but 
the predictive accuracy was deemed to be low (12) . There are international guidelines 
highlighting association of PAPP-A and small for gestational age (4). 
 
Thus, as we have become aware that complications of late pregnancy may have some 
relation with the first half of pregnancy, it seems reasonable to focus on this period to 




The placenta is a unique and highly specialized organ of exchange in pregnancy 
that has an important role in the normal growth and development of the fetus. It acts 
to provide oxygen and nutrients to the fetus, whilst removing carbon dioxide and 
other waste products. It metabolizes several substances and can release metabolic 
products into maternal and/or fetal circulations (13-16). The placenta plays a pivotal role 
in protecting the fetus against certain xenobiotic molecules, infections and maternal 
diseases. The placenta releases hormones into both the maternal and fetal circulations to 




1.2 Structure of Placenta: 
 
 
The placenta is formed from two distinct genetic origins: the decidua (maternal part of 
placenta) that develops from the uterine tissue, and the chorion (fetal part of placenta), 
3  
which develops from the blastocyst (18). Between these two layers is a sinus called the 
intervillous space within the placenta that fills with maternal blood supplied by the 
uterine arteries. The maternal blood bathes tree-like structures called chorionic villi 
which originate from the chorion and serve as the interface where gas and nutrient 
exchange takes place between the fetal and maternal circulatory systems. Some villi 
span the distance of the intervillous space, serving as a place of attachment to the 
uterine wall and so are termed “anchoring” villi, whereas others float freely in the 
maternal blood and are termed “floating” villi (18, 19). 
 
 
Chorionic villi are made up of several different cell types. These include the fetal 
endothelial cells lining the fetal blood vessels, the villous mesenchyme, the villous 
cytotrophoblast (CT) and the multinucleated syncytiotrophoblast (ST), which makes up 
the outermost cellular layer of the chorionic villi and is in direct contact with the 
maternal blood (10-12). The ST is maintained by differentiation and fusion of the 
highly proliferative CT, which makes up the layer immediately beneath the ST (6, 
19, 20). 
 
Extravillous trophoblast (EVT) is another trophoblast cell type that arises from the 
proliferation and differentiation of stem cells within the CT layer (10). The cells in this 
layer are key players in the crucial processes of normal placental development, namely 
EVT migration and invasion, and spiral artery remodeling. EVT cells penetrate the 
maternal decidua and first third of the myometrium where they invade and restructure the 
maternal uterine arteries (19, 21). This invasion also results in replacing the uterine 
vessel endothelial cells, transforming the blood vessels into spiral arteries of wider 
diameter which can accommodate the blood flow required to sustain pregnancy (19, 21, 
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22). This process occurs between 6 and 18 weeks of gestation, and is more or less 
complete before 20 weeks of gestation(23). 
 
Thus, the placenta has an essential role in determining the outcome of pregnancy. Early 
prediction of potential placental insufficiency before the establishment of its 













The Human placenta produces a wide variety of specific proteins, which do not occur 
or occur only in trace amounts in normal sera in non-pregnant state. During pregnancy, 
they appear in the maternal blood stream or their concentrations are strongly elevated 
(24). One of many such proteins is ‘Pregnancy-associated plasma protein-A’ (PAPP-A). 
It is also known as Pappalysin-1 A. 
 
 
2.1 Pregnancy associated Plasma Protein A (PAPP-A) 
 
PAPP-A was originally isolated in 1974, as one of four proteins of placental origin 
found in high concentrations in the blood of pregnant women (25). Soon after its 
discovery, PAPP-A was studied with relation to the adverse pregnancy outcomes in 
later pregnancies but failed to create any significant impact. A new period of PAPP-A 
research appeared after Brambati et al in 1991, described its decreased levels in first 
trimester of pregnancy with fetus affected by Down syndrome (26). Currently PAPP-A 
is a well-established marker used in the screening for Down’s syndrome in the first 
trimester and there has been emerging evidence that serum PAPP-A levels early in 
pregnancy could predict adverse pregnancy outcomes (4, 27). 
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2.2 Structure of PAPP-A 
 
PAPP-A is a glycoprotein that is encoded by the PAPP-A gene which is located on 
human chromosome 9q33.1(28). It is secreted as a disulphide-bound homodimer which 
has a molecular weight of 400,000 g/mol (29, 30). 
 
 
The 1547-residue PAPP-A polypeptide (31) is secreted as a disulfide-bound dimer of 
400 kDa (29). PAPP-A contains the zinc-binding motif and belongs to the metzincin 
superfamily of metalloproteinases which includes the astacins, the reprolysins, the 
serralysins, and the matrix metalloproteinases (21, 32). PAPP-A is the first member of 
a fifth metzincin family, the pappalysins (33). Along with a proteolytic domain, the 
PAPP-A subunit has three lin-notch repeats (LNR-1–3, each of 26–27 residues) and 
five complement control protein modules (CCP-1–5, each of 57–77 residues) who 
fecilitate binding of PAPP-A to heparin sulfates present on cell surfaces (31, 34). 
 
 
In pregnancy serum, most of the PAPP-A (99%) (29) is covalently bound in a 2:2 




During pregnancy, PAPP-A and proMBP are expressed in significant amounts in the 
human placenta (37). While PAPP-A is mainly expressed in the syncytiotrophoblast, 
ProMBP is expressed in extravillous cytotrophoblasts. ProMBP is secreted from these 
extravillous cytotrophoblasts without propeptide cleavage (38). Hence the PAPP- A/ 
proMBP complex formation occurs in the extracellular environment, possibly on the 





2.3 Mode of action of PAPP-A 
 
PAPP-A enhances the bioavailability of insulin-like growth factor (IGF) locally by 
cleaving the inhibitors IGFBP-4 and -5 (insulin-like growth factor-binding protein-4 
and -5) (39-42). IGF is mitogenic and anti apoptotic and is vital for the growth of 
human cells in most tissues (43, 44). It has a pivotal role in the development of the 
placenta and spiral artery remodelling as it stimulates CT proliferation and EVT 




2.3 Clinical application of PAPP-A 
 
Detectable levels of maternal PAPP-A are demonstrated soon after the 
implantation and the levels of PAPP-A increase throughout pregnancy. It 
doubles in about 3–4 days during the first trimester and maximum levels are 
reached at term (46, 47). 
 
 
Due to the exponential increase in PAPP-A levels during the first trimester, the 
interpretation of a given value would be very much dependent on the gestational age. 
The Common practice is to use the unit called MoM (Multiples of Median). A multiple 
of the median (MoM) is a measure of how far maternal PAPP-A concentration deviates 
from the expected normal median level for a pregnancy of the same gestational age. 
Hence MoM would be a gestational age independent expression of PAPP-A 
concentration. Along with gestational age, the following maternal and pregnancy-
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associated characteristics are also known to affect the maternal serum concentration of 
PAPP-A: ethnicity, chronicity, assisted versus spontaneous conception, maternal pre-
pregnancy weight, maternal smoking during pregnancy, parity, and history of previous 
pregnancy with trisomy 21, 18, or 13. MoM values would be further adjusted to the 
above factors as well. 
 
Maternal serum PAPP-A  is a well-established serum marker  and is used  in first-
trimester screening programs for chromosomal abnormalities  which are 
characterized by low maternal serum PAPP-A levels. There are no 
pathophysiologic explanations available for these low PAPP-A values. The 




Studies have tested the hypothesis that low maternal serum levels of PAPP-A in the 
first trimester can predict adverse pregnancy outcomes associated with poor placental 
function (6, 48-51). International Guidelines on “The Investigation and Management of 
the Small for Gestational Age Fetus” have recommended that pregnant women with a 
serum PAPP-A <0.4MoM (5th centile) in the first trimester receive increased ultrasound 
surveillance for fetal growth disorders (4) . However, contradictory results have been 
observed in other publications (51, 52). A comprehensive systematic review concluded 
PAPP A has low accuracy in predicting small for gestation age fetus but could be a 




association of first trimester fetal biometry [nuchal translucency (NT) and crown rump 




The clinical applications of biomarkers including maternal PAPP-A is rapidly 
expanding field and there are variations in the research designs and inconsistencies in 
the outcomes assessed, hence, there is a lack of clear collated up-to-date summaries of 
the existing literature. There is still uncertainty about the best prediction and 
management strategies. A systematic review combined with a contemporary 
comprehensive study of a large population at a tertiary care hospital will improve our 
understanding in the relation between PAPP-A levels and pregnancy outcome. As 
measuring PAPP-A levels is part of first trimester screening of Down’s syndrome, 
there would no extra cost in using it as a predictor of the pregnancy outcome if a 
correlation is established. This would provide an effective means when combined with 
interventions/surveillance to reduce adverse pregnancy outcome. 
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This thesis will aim to perform: 
 
1. A systematic review to assess the predictive accuracy of first trimester serum 
PAPP-A for SGA and other adverse pregnancy outcomes measured in terms of 
pregnancy loss, preterm birth, and intra-uterine death (IUD) and hypertensive 
disorders of pregnancy. 
 
 
The aim of the review is to determine the predictive accuracy of first trimester 





 Population: Pregnant women any health care setting, any level of risk. 
 
 Tests: Serum pregnancy associated plasma protein A measured in the first 
trimester (<14 weeks of pregnancy). 
 Reference standard/outcome: Birth weight, birth weight centile (population or 
customized), maternal (pre-eclampsia, pregnancy induced hypertension, 
gestational diabetes, abruption) and pregnancy outcomes (miscarriage, stillbirth, 
preterm delivery). 
 Study design: Observational test accuracy studies (cohorts, case-control 
prospective) allowing generation of 2x2 tables of accuracy. Case series <10 
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cases and case-control studies defined by reference standard outcome were 
excluded, these study designs have been shown to be associated with bias (49). 
 
 
2. Retrospective cohort study to examine the association and to assess the 
predictive accuracy of maternal serum PAPP-A along with CRL and NT in first 
trimester for adverse pregnancy outcome in the population at BWNFT. 
 
 
Population: Pregnant women delivering at the Birmingham Women’s Hospital NHS 
Foundation Trust (BWNFT) between 1st September 2011 and  31st March 2015. 
Setting: An NHS Foundation Trust in the West Midlands, which is a secondary and 
tertiary care hospital serving the region of West Midlands in the UK. 
Study design: A retrospective analysis of independent databases for PAPP-A in the 
first trimester (Down’s syndrome screening), first trimester dating ultrasound and 
second trimester (CRIS) pregnancy outcome database (K2) and Genetics database. 
Outcomes: small for gestational age (birth weight <10th customized centile), and 




Analysis: Unadjusted logistic regression analysis would be used to estimate the odds 
ratio (OR) for each binary outcome for two patients who differ by one unit of the 
potential prognostic factor (PAPP-A/NT/CRL). The three potential prognostic 
factors would be assessed in separate logistic regression models. Multivariable 
logistic regression analyses will be additionally adjusted for known prognostic 
factors and potential confounders. In the fully adjusted analyses, the linearity 
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assumption of the prognostic effects will be assessed and logistic regression analysis 
to develop prediction model. 
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CHAPTER 4: ASSOCIATION OF SERUM PAPP-A 
LEVELS IN FIRST TRIMESTER WITH SMALL FOR 
GESTATIONAL AGE NEONATE AND OTHER ADVERSE 






Adverse pregnancy outcomes [stillbirth, preterm birth (PTB), small for gestational age 
(SGA), and hypertensive disorders of pregnancy] have a major psychological impact 
for the family as well as an increased cost for the healthcare system. Accurate methods 
of predicting these outcomes would allow health professionals to provide increased 
surveillance and offer optimum management, which could possibly improve the 




Pregnancy associated plasma protein A (PAPP-A) is a placental glycoprotein 
produced by syncytial trophoblast, which cleaves insulin-like growth factor binding 
protein 4 (IGFBP4) and is a positive regulator of insulin-like growth factors (IGFs) 
(53). Biochemical measurement of placental derived factors has been suggested as  a 
means to improve fetal and maternal outcome of pregnancy. Previous studies have 
tested the hypothesis that low maternal serum levels of PAPP-A in the first trimester 
can predict adverse pregnancy outcomes associated with poor placental function (5, 6,  
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49-51). The recently published Royal College of Obstetricians and Gynaecologists 
(RCOG) Green top Guidelines assessed all the available evidence prior to their 
publication in 2013 and recommended that in women with a serum PAPP-A <0.415 
multiples of the median (MoM) (5th centile) in the first trimester receive increased 
ultrasound surveillance for growth disorders (4). In 2010 first trimester combined 
screening was routinely introduced in the United Kingdom as the recommended 
screening for Down’s syndrome (27). This test involves assay of PAPP-A between 10 
and 13+6 weeks. Since this time, there has been a substantial increase in the number 
of published articles related to this placental analyte and thus a need to systematically 




When assessing a biomarker, it is important to assess whether there is any prognostic 
association between the “analyte” and outcomes of interest before considering the 
predictive ability of the biomarker to predict the outcome of interest in an individual 
(54). The aim of this systematic review and meta-analysis is to improve our 
understanding of the association between first trimester maternal serum PAPP-A levels 
and pregnancy outcomes and where appropriate to evaluate the predictive ability for 




A protocol driven systematic review was performed in accordance with published 
guidelines (55-59). The reporting of the review meets the criteria specified in the 




4.2.1 Framing the question 
 
A clearly defined research question is an essential element for the systematic review. This 
ensures that the review is correctly designed and that the question is fully answered. It has 
four key components: the population under study, the test or intervention, the reference 
standard or comparator and the type of study designs to be included. The questions posed 
in this systematic review are as follows: 
 Population: Pregnant women any health care setting, any level of risk. 
 
 Tests: Serum pregnancy associated plasma protein A measured in the first 
trimester (<14 weeks of pregnancy) 
 Reference standard/outcome: Birth weight, birth weight centile (population or 
customized), maternal (pre-eclampsia, pregnancy induced hypertension, 
gestational diabetes, abruption) and pregnancy outcomes (miscarriage, stillbirth, 
preterm delivery). 
 Study design: Observational test accuracy studies (cohorts, case-control 
prospective) allowing generation of 2x2 tables of accuracy. Case series <10 
cases and case-control studies defined by reference standard outcome were 
excluded, these study designs have been shown to be associated with bias (60) 
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4.3 Identification of the literature 
 
The search strategies used relevant medical subheadings (MeSH), text words and 
word variants for PAPP-A and each adverse pregnancy outcomes - small for 
gestational age, preterm birth, pre-eclampsia, stillbirth and gestational diabetes. The 






A literature search was performed in electronic databases from inception till March 
2015. No language restrictions were applied. We searched Embase, MEDLINE, 
CINAHL (current nursing and allied health literature) and Web of Science (grey 
literature) using combinations of relevant medical subject heading (MeSH) terms, 




4.3.2 Definitions of adverse pregnancy outcomes: 
 
 
1. Preeclampsia, defined as per ISSHHP guidelines as de-novo hypertension at or 
after 20 weeks’ gestation (at least 2 readings of Blood Pressure >140 mmHg systolic or 
>90 mmHg diastolic) with proteinuria (spot urine protein/creatinine >30 mg/mmol [0.3 
mg/mg] or >300 mg/day or at least 1 g/L [‘2 +’] on dipstick testing) (57). persistently 
elevated systolic (> 140 mmHg) or diastolic (> 90 mmHg) blood pressure and 
proteinuria (> 0.3 g/24h or spot urine protein to creatinine ratio ≥ 30 mg/ mmol) arising 
after the 20th week of pregnancy (61). 
 
17  
2. Small for gestational age: Defined as birth weight below the 10th, 5th, or 3rd 
percentile for gestational age (62). 
3. Stillbirth: Fetal demise at or after 24 completed weeks 
4. Preterm birth: Birth before 37 completed weeks of gestation. 
5. Gestational Diabetes: Diabetes in pregnancy diagnosis was made on the basis of 
world health organisation recommendations i.e. one or more of the following criteria 
were met: Fasting plasma glucose ≥ 7.0 mmol/l (126 mg/ dl) or 2-hour plasma glucose 
≥ 11.1 mmol/l (200 mg/dl) following a 75g oral glucose load or random plasma glucose 
 





The database search performed used terms for PAPP-A/pregnancy associated plasma 
protein A and combined with the following adverse pregnancy outcomes: miscarriage, 
SGA, PET, pre term birth, gestational diabetes. PAPP-A/ pregnancy associated plasma 
protein A was combined with each of the adverse pregnancy outcomes separately (along 
with their synonyms) using the AND operator. (The individual search strategies for 
adverse outcome are outlined in detail in appendix 1). 
 
 
The reference lists of all included primary and review articles were examined to identify 




A comprehensive database collating all citations was constructed using Endnote 7 
(Thomson Reuters) (64). 
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4.3.3 Study selection and data extraction 
 
The extraction of a study’s findings was conducted using a pre-designed extraction form 
(Appendix 2). Once the paper was selected after the first screening, further data from the 
selected papers were recorded on an Excel spreadsheet. Each selected paper was 
evaluated for its quality using two quality assessment tools for diagnostic accuracy 
studies namely QUADAS -2 (Quality assessment of diagnostic accuracy studies -2) 




The titles and abstracts of the citations were scrutinized by three independent reviewers 
(Dr Rachel Katherine Morris (RKM), Dr Ashwini Bilagi (AB) and Pooja Devani (PD) 
partly in duplicate). No language restrictions were applied to the study. The reference lists 
of selected studies and review articles were checked and additional relevant articles were 
obtained. All foreign language papers were translated (see acknowledgements). Copies of 
full manuscripts of the citations that were likely to meet the selection criteria were 
obtained. The studies which met predefined and explicit criteria regarding populations, 
tests, reference standards and study design were selected. Data were extracted on study 
characteristics, quality assessment criteria and results for 2x2 tables (true positive, false 
positive, false negative, true negative) comparing the same threshold of PAPP-A with an 
individual outcome and entered in to an Excel spread sheet in duplicate by three 
reviewers (AB, RKM and PD). When disagreements occurred, the reviewers met and if a 
consensus could not be reached the opinion of a fourth reviewer (Professor Mark Kilby) 
was sought. In the case of duplicate publications, the most recent or up to date manuscript 
was selected. 
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4.3.4 Study Quality assessment 
 
All studies meeting the pre-defined selection criteria were assessed for methodological 
and reporting quality, defined as confidence that the study design, conduct, analysis and 
reporting minimized any bias in the estimation of the association. Quality assessment 
was based on published guidelines for reporting of diagnostic accuracy studies 
(STARD) and methodological quality (QUADAS-2) (65-68). The details of guidelines 
are reported in appendix 3 and Appendix 4. The methodological quality items were 
adopted for the review question and two authors independently judged each quality 
item. In case of discrepancies, consensus was reached by discussion. 
 
 
In the assessment of study quality, assessments were made in the domains of patient 
selection, index test, reference standard and flow and timing, assessing risk of bias and 
applicability as per QUADAS-2 (67). For the population, consecutive or random 
recruitment of pregnant women was ideal. Prospective recruitment was considered to 
introduce less bias than retrospective recruitment. The description of the population was 
considered ideal if there was sufficient information about the pregnant women given to 





The quality of performance and reporting of the index standard (PAPP-A) was assessed 
considering the processes reported for storage of the maternal serum sample if needed 
and the immunoassay analyser used in the lab to quantify the levels of serum PAPP A. 
For the reference standard, any outcome relating to maternal, pregnancy or neonatal 
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outcome was considered and information collected on method of determination of 




Ideal study designs were trials or cohort studies, case-control studies were only included 
when cases were not determined by references standard/outcome as it has been shown 
that this type of study design can affect accuracy (60). Verification bias was assessed 
using a flow chart for each study which documented the number of eligible women for 
the study, the number of women subjected to the index test, the number of women 
receiving the reference standard and the number of exclusions, withdrawals and 
uninterpretable results. Ideal verification was when all women could be accounted for 




The assessment of quality is represented by a bar chart. No attempt was made to apply 
a quality score as this has been shown to have little validity and quality was not used as 
an aspect for inclusion/exclusion of studies from meta-analysis; instead an individual 
assessment was made and this was used to inform investigations into heterogeneity in 
results and sub-group analysis where appropriate (69). 
 
 
4.3.5 : Data synthesis and analysis 
 
From the 2x2 tables the following were calculated with 95% confidence intervals (CI) 
for individual studies: odds ratio (OR), sensitivity, specificity and the likelihood ratios 
(LR). Results were pooled among groups of studies with similar characteristics, the 
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same threshold for the index test and same reference standard definition and threshold. 
Studies also reported a composite adverse pregnancy outcome, these studies were 
included in a meta-analysis if it could be ensured that individuals were only counted 
once and that the individual outcomes of the composite were all a similar magnitude 
and direction of effect across the studies (70). The OR was selected as the summary 
statistic, as it represents the effect of the exposure on the odds in an unbiased fashion 
and enables the results of both case-control and cohort studies to be included and 
provides a measure of the test’s prognostic ability (71). 
Data were first displayed as forest plots of the OR and 95% CI to allow a visual 
inspection for heterogeneity. Statistical heterogeneity was assessed using the I2 statistic 
where I2>50% is significant (72). Random effects meta-analysis was used throughout 
in anticipation of significant clinical and statistical heterogeneity. Where there were 
zero cells within a table a value of 0.5 was added to allow the calculation of log ORs 
and their variances for meta-analysis (73). 
 
 
To explore for the presence of funnel plot asymmetry (small study effects), and thus 
potential publication bias, the Peters test was performed in each meta-analysis(74). 
Where there was a moderate statistically significant association between PAPP-A and 
an outcome measure (defined as OR>2 and 95% CI >1) then sensitivity, specificity and 
likelihood ratios were considered, using data from the 2x2 tables. Predictive summary 
measures were synthesized using the bivariate random effects prediction model where 
there were at least 4 studies in the meta-analysis and univariate meta-analysis where this 
was not possible (75). These measures assess the predictive ability of the test i.e. 
whether the test can accurately discriminate between those who do and those who do 
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not have the adverse outcome (sensitivity and specificity) and by how much a positive 
or negative test result modifies the odds of a poor outcome (likelihood ratios) (56). 




All analyses were performed in STATA 10.0 (StataCorp, College Station, TX, USA) 
using the metan, metandi and metabias commands (76-78). Univariate analyses were 





Figure 1 demonstrates the study selection process with 32 studies being included 
reporting on 175,240 pregnancies (5, 6, 50, 52, 81-105). All studies were performed in 
secondary or tertiary care settings in a low risk or unselected population. All were 
singleton pregnancies except n=5 studies where it was not clear that multiple 
pregnancies were excluded. All but six studies excluded fetuses with chromosomal or 
structural anomalies. 
23  
Figure 1: Study selection process for systematic review of association of prediction 
of first trimester serum pregnancy associated plasma protein A (PAPP-A) with 






Potentially relevant citations identified from electronic searches to 
capture primary articles on all studies assessing first trimester serum 
PAPP-A and pregnancy outcome 
 
N= 1715 





References excluded after screening titles and/ or abstracts 
 
N= 34 
Primary articles retrieved for detailed evaluation 
 
- from electronic searches N= 271 
- from reference lists N= 5 
Articles excluded n= 244 
- Not prediction/ not test accuracy n= 66 
- Reviews/ letters/ comments/ editorials n= 37 
- Not PAPPA n= 7 
Primary articles included in systematic review n= 32 
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All studies were observational and non-interventional, designs were: n=23 cohort, n=5 
case-control and n=4 unclear. Recruitment was prospective in n=13, retrospective in 
n=16 and unclear in n=3. PAPP-A was performed between 8-14 weeks and various 
thresholds were reported including centile cut-offs and multiples of the median (MoM). 
Outcomes included birth weight <10th (n=17 studies), <5th (n=15) or <3rd (n=3) centile 
and >90th (n=2) centile. Maternal outcomes included pre-eclampsia (n=11), pregnancy 
induced hypertension (n=6), preterm birth (<37 (n=22), <34 (n=2) and <32 (n=3) 
weeks), gestational diabetes (n=1), abruption (n=4) and pregnancy loss <24 weeks 
(n=4). Fetal outcomes included stillbirth >24 weeks (n=8). Six studies reported results 
for a composite adverse pregnancy outcome. The details of papers included in the study 





Figure 2 displays the bar charts for methodological quality.  The left side bar diagram 
describes the risk of bias and the right side bar diagram explains the concerns regarding 
applicability. The left bar diagram  has flow and timing, reference standard, index test 
and patient selection on y axis and on x axis are the number of papers. The right side 
bar diagram has reference standard, index test and patient selection on y axis and 
number of papers on the x axis. For patient selection two studies were assessed as high 
risk of bias (89, 102). In the other three domains (index test, reference standard and 
flow and timing) all studies were judged overall to have a low risk of bias. When 
assessing applicability, there was only one domain in which there was concern with one 
study having a high risk (80). The overall high quality of the included studies meant that 
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Figure 2: Bar chart demonstrate methodological quality of included studies in 
systematic review of association of pregnancy associated plasma protein A with 
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4.4.1: Prognostic association 
 
Table 1 summarizes the OR and 95% CI for all analyses. Assessing the previously 
recommended threshold of PAPP-A<5th centile in the first trimester (4, 106) gave 
increased odds of the following birth weight outcomes: Birth weight <10th centile OR 
2.08 (95% CI 1.89 – 2.29), Birth weight <5th centile OR 2.83 (95% CI 2.52 – 3.18) and 
Birth weight <3rd centile OR 2.76 (95% CI 1.78 – 4.28). For other adverse pregnancy 
outcomes, the increased odds were: PET OR 1.94 (95% CI 1.63 – 2.30), PTB <37 
weeks OR 2.09 (95% CI 1.87 – 2.33), pregnancy loss prior to 24 weeks OR 2.50 (95% 
CI 1.81– 3.47) and stillbirth after 24 weeks gestation OR 2.40 (95% CI 1.45 – 3.99). 
 
For the composite, adverse outcome, the increased odds of an adverse outcome was 
OR 3.31 (95% CI 1.80 – 5.11). Where data was available to look at odds of an adverse 
outcome with PAPP-A<1st centile this demonstrated increasing odds with decreasing 
PAPP-A (Appendix 14). Three of the analyses demonstrated significant heterogeneity 







Table 1: Meta-analysis summary of studies for systematic review of association and prediction of first trimester maternal serum pregnancy associated plasma 
protein A (PAPPA) and adverse pregnancy outcomes.  
Pregnancy 




























































          <10th centile 
*
 7 44316 1.88 1.72-2.05 0.16 0.14 -0.19 0.90 0.89 - 0.90 1.64 1.45 - 1.88 0.92 0.90 - 0.95 
<5th centile 
*
 12 59927 2.08 1.89-2.29 0.13 0.08 -0.2 0.94 0.90 - 0.96 1.96 1.58 -2.43 0.93 0.89 - 0.98 
< 1st centile 2 39671 3.40 2.70 - 4.26 0.03 0.02 -0.04 0.99 0.99 - 0.99 3.49 2.51 - 4.89 0.98 0.98 - 0.99 

























0.90 - 1.04 
 
 







                     
<10th centile 4 39714 2.29 2.01 - 2.60 0.20 0.18 - 0.22 0.90 0.90 - 0.90 2.17 1.64 - 2.87 0.90 0.85 - 0.94 
<5th centile
*
 11 72245 2.83 2.52-3.18 0.22 0.10 - 0.41 0.92 0.84 - 0.96 2.65 2.35 - 2.99 0.85 0.74 - 0.98 
 <1st centile 2 45750 4.66 3.61 - 6.01 0.04 0.03 - 0.05 0.99 0.99 - 0.99 4.52 3.53 - 5.78 0.97 0.96 - 0.98 
<0.5MoM 2 4550 2.12 1.53 - 2.95 0.25 0.19 - 0.32 0.86 0.85 - 0.87 1.99 1.23 - 3.22 0.84 0.68 -1.03 
<0.3MoM 2 22464 3.13 2.30 - 4.26 0.12 0.09 -0.16 0.96 0.95 - 0.96 2.89 2.21 - 3.79 0.92 0.88 - 0.97 
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Pregnancy 




























































                     
<5th centile 2 8108 2.76 1.78 - 4.28 0.12 0.08 -0.18 0.95 0.95 - 0.96 2.58 1.75 - 3.79 0.93 0.88 -0.98 
<0.5 MoM 2 3692 1.89 1.19 - 3.01 0.23 0.15 - 0.32 0.87 0.85 - 0.88 1.69 1.18 - 2.42 0.89 0.80 -0.99 



























Birth weight  
 





                     
 <10th centile 2 35545 0.50 0.35 - 0.71 0.05 0.04 -0.08 0.90 0.90 -0.90 0.53 0.38 - 0.74 1.05 1.03 - 1.08 
< 5th centile 2 35545 0.42 0.24 - 0.72 0.02 0.01 - 0.04 0.95 0.95 - 0.95 0.44 0.25 -0.75 1.03 1.02 - 1.04 







                     
< 10th centile 3 38956 1.42 1.18 - 1.72 0.14 0.12 - 0.16 0.90 0.89 - 0.90 1.55 1.06 - 2.27 0.94 0.88 - 1.01 
 < 5th centile
*
 8 132076 1.94 1.63-2.30 0.16 0.09 - 0.28 0.92 0.85 - 0.96 1.95 1.48 - 2.56 0.91 0.86 - 0.97 
< 1st centile 2 45750 2.27 1.43 - 3.62 0.02 0.01 - 0.04 0.99 0.99 - 0.99 4.91 0.60 - 40.19 0.95 0.83 - 1.08 






























































































































































                     
< 10th centile 2 5561 2.83 1.71 - 4.68 0.24 0.15 - 0.34 0.90 0.19 - 0.91 2.47 1.68 - 3.63 0.91 0.73 - 1.13 
< 0.5 MoM 2 2124 5.07 2.78 - 9.27 0.47 0.31 - 0.62 0.86 0.84 - 0.87 2.80 0.25 - 31.57 0.43 0.03 -7.48 
< 0.4 MoM 2 877 2.68 1.40 - 5.10 0.18 0.1 - 0.28 0.92 0.90 - 0.94 2.31 1.37 - 3.90 0.91 0.83 - 1.00 
             









               
  
     
< 10th centile 3 38956 1.52 1.35 - 1.71 0.15 0.13 - 0.16 0.90 0.89 - 0.90 1.45 1.31 - 1.60 0.95 0.93 - 0.97 
 < 5th centile
*
 7 66133 2.09 1.87-2.33 0.16 0.09 - 0.29 0.91 0.83 - 0.96 1.84 1.41 - 2.39 0.92 0.87 - 0.98 
< 1st centile 2 45750 3.63 2.89 - 4.55 0.03 0.03 - 0.04 0.99 0.99 - 0.99 4.28 1.50-12.25 0.97 0.94 - 1.00 
 < 0.6 MoM 2 4938 1.69 1.36 - 2.11 0.32 0.27 - 0.37 0.78 0.77 - 0.80 1.48 1.21 - 1.80 0.87 0.81 - 0.94 
< 0.5 MoM 3 2946 3.02 2.16 - 4.22 0.30 0.23 - 0.37 0.87 0.86 - 0.88 2.31 0.62 - 8.55 0.75 0.52 - 1.09 
< 0.4 MoM 3 12231 1.94 1.50 - 2.49 0.10 0.08 - 0.12 0.95 0.95 - 0.95 1.85 1.48 - 2.32 0.95 0.90 - 1.00 
< 0.3 MoM 3 13060 2.11 1.50 - 2.95 0.05 0.04 - 0.07 0.98 0.98 - 0.98 1.86 0.95 - 3.64 0.98 0.96 - 1.00 


































































































                     
< 5th centile 2 13012 2.51 1.48 - 4.25 0.17 0.13 - 0.21 0.90 0.90 - 0.90 1.69 1.31 -2.16 0.93 0.88 - 0.97 
< 1st centile 1 7769 2.37 0.57 - 9.81 0.02 0.02 - 0.07 0.99 0.99 - 0.99 2.34 0.58 - 9.41 0.99 0.96 - 1.02 


















                     
<10th centile 2 35623 1.82 1.35 - 2.45 0.17 0.13 - 0.21 0.90 0.90 - 0.90 1.69 1.31 - 2.16 0.93 0.88 - 0.97 
< 5th centile 3 42690 2.25 1.60 - 3.17 0.12 0.09 - 0.16 0.95 0.94 - 0.95 1.99 1.49 - 2.65 0.94 0.91 - 0.98 
< 1st centile 1 33395 3.26 1.60 - 6.65 0.03 0.01 - 0.06 0.99 0.99 - 0.99 3.19 1.6 - 6.36 0.98 0.96 - 1.0 



































































































47916                     
             
< 10th centile 2 33593 1.84 1.08 - 3.12 0.17 0.10 - 0.26 0.90 0.90 - 0.90 4.74 0.43 - 52.33 0.85 0.43 - 1.70 
 < 5th centile
*
  5 44575 2.40 1.45-3.99 0.18 0.08 - 0.36 0.88 0.80 - 0.94 1.58 0.67 - 3.71 0.92 0.78 - 1.09 
<1st centile 1 33395 3.04 0.96 - 9.63 0.03 0.01-0.09 0.99 0.99 - 0.99 2.97 0.97 - 9.09 0.98 0.94 - 1.01 
 < 0.5 MoM 2 2119 5.74 0.81 - 40.70 0.50 0.01 - 0.99 0.85 0.84 - 0.87 4.10 1.22 - 13.70 0.71 0.22 - 2.26 
             
 
Pregnancy loss 
≤24 weeks 4 49986                     
             
 < 10th centile 2 38692 2.12 1.62 - 2.77 0.19 0.15 - 0.24 0.90 0.90 -0.90 1.91 1.53 - 3.37 0.90 0.85 - 0.95 
 < 5th centile 2 38692 2.50 1.81 - 3.47 0.12 0.09 - 0.16 0.95 0.95 - 0.95 2.25 1.47 - 3.46 0.94 0.99 - 1.00 
<1st centile 1 33395 5.48 3.28 - 9.17 0.05 0.03 - 0.09 0.99 0.99 - 0.99 5.24 3.21 - 8.53 0.96 0.93 - 0.98 












                     
< 5th centile 1 5243 4.17 2.00 - 8.69 0.18 0.09- 0.32 0.95 0.94 - 0.96 3.59 1.97 - 6.55 0.86 0.75 - 0.98 
















































































































                     
< 5th centile 2 2565 2.73 0.81 - 9.23 0.31 0.09 - 0.61 0.82 0.8 - 0.83 2.74 0.62 - 12.17 0.80 0.56 - 1.15 









                     
< 10th centile 2 1076 4.50 2.55 - 7.95 0.29 0.18 - 0.41 0.92 0.9 - 0.93 3.48 2.28 - 5.32 0.78 0.67 - 0.91 
< 5th centile 3 13431 3.31 2.76 - 3.97 0.12 0.1 - 0.14 0.96 0.96 - 0.96 3.05 2.59 - 3.59 0.92 0.9 - 0.93 




























PAPPA - pregnancy associated plasma 
protein A 
          MoM multiples of median 
           * bivariate meta-analysis 








Forest plots for the main analyses are shown in Figures 3 to 8. Inspection of the forest 
plots and table of characteristics could demonstrate no obvious cause for the 
demonstrated significant heterogeneity (Birthweight <10th, PET and PTB). Peter’s test 




Figure 3: Forest plot for association (odds ratio) of pregnancy associated plasma 











Figure 4: Forest plot for association (odds ratio) of pregnancy associated plasma 















Figure 5: Forest plot for association (odds ratio) of pregnancy associated plasma  












Figure 6: Forest plot for association (odds ratio) of pregnancy associated plasma 















Figure 7: Forest plot for association (odds ratio) of pregnancy associated plasma 











Figure 8: Forest plot for association (odds ratio) of pregnancy associated plasma 







4.4.2: Predictive ability 
 
Table 1 also summarises the sensitivity, specificity, likelihood ratios and 95% CI for all 
analyses. Bivariate meta-analysis was possible for 6 test-outcome combinations: PAPP- 
A <10th centile and birth weight <10th; PAPP-A <5th centile and birth weight 10th  and 
<5th centile, pre-eclampsia, preterm birth <37 weeks and stillbirth >24 weeks and the 
 
hierarchical summary receiver operating characteristic curves (HSROC) are shown in 
Figure 7. Considering those analyses where a moderate association had been 
demonstrated (OR > 2.0 and lower CI > 1.0) the following predictive abilities were 
demonstrated all with a threshold of PAPP-A < 5th centile: Birthweight <10th centile 
LR+ve 1.96 (95% CI 1.58 -2.43), LR-ve 0.93 (95% CI 0.89 – 0.98); Birthweight <5th 
centile LR+ve 2.65 (95% CI 2.35 -2.99), LR-ve 0.85 (95% CI 0.74 – 0.98); PTB <37 
 
weeks LR+ve 1.84 (95% CI 1.41 – 2.39), LR-ve 0.92 (95% CI 0.87 – 0.98) and stillbirth 
 
>24 weeks LR+ve 1.58 (95% CI 0.67 – 3.71) and LR-ve 0.92 (95% CI 0.78 – 1.09). 
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Figure 9: Hierarchical summary receiver operating curve (HSROC) for pregnancy 
associated plasma protein A (PAPP-A) and adverse pregnancy outcome 
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The predictive ability of  PAPP-A is poor in an individual with only a small increase 
and minimal or no decrease in likelihood of disease with a positive or negative test. This 
can be converted to a probability of an adverse outcome for a low risk nulliparous 
woman (i.e. no known prior risk) in an unselected population with 8000 deliveries a 
year after a positive test (i.e. posterior test probability) using a nomogram 
(http://araw.mede.uic.edu/cgibin/testcalc.pl)  (Table 2).  
Thus, following a PAPP-A in the first trimester less than <5th centile a woman would 
have a 1 in 5.6 chance of an SGA baby (birth weight <10th centile) and a 1 in 3.7 of any 
adverse outcome. With lower levels of PAPP-A <1st centile the risks are considerably 
increased with a 1 in 3.6 chance of an SGA baby, 1 in 11 chance of pre-eclampsia, 1 in 
3.7 chance of preterm birth (<37 weeks), 1 in 10 chance of late miscarriage and a 1 in 
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(number with 
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18% (1 in 5.6) 
 
9% (1 in 1.1) 













12% (1 in 8.2) 
 
4% (1 in 1.0) 
Pre-eclampsia 1.95 1.48 - 2.56 0.91 0.86 - 0.97 2 4% (1 in 26) 2% (1 in 1.0) 













12% (1 in 8.1) 
 
7% (1 in 1.1) 













4% (1 in 25) 
 
2% (1 in 1.0) 













3% (1 in 36) 
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after negative test % 
(number with negative 
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4% (1 in 23) 
 
2% (1 in 1.0) 














27% (1 in 3.7) 
 
10% (1 in 1.1) 
 
PAPP-A <1st centile 
       













28% (1 in 3.6) 
 
10% (1 in 1.1) 













19% (1 in 5.2) 
 














9% (1 in 11) 
 
2% (1 in 1.0) 













27% (1 in 3.7) 
 
8% (1 in 1.1) 













5% ( 1 in 18) 
 

































after positive test % 
(number with 




after negative test % 
(number with negative 
test without outcome) 









0.96 - 1.0 
1.4 
 
4% (1 in 23) 
 
1% (1 in 1.0) 
Pregnancy loss < 24 
weeks 




10% (1 in 10) 
 
2% (1 in 1.0) 
Stillbirth > 24 weeks 2.97 0.97 - 9.09 0.98 0.94 - 1.01 0.47 1% (1 in 72) 0% (1 in 1.0) 
PAPP-A - pregnancy associated plasma protein  
MoM multiples of 
median 
       
* bivariate meta- 
analysis 
       
$ Prevalence data obtained from ONS 2014 
(http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/birthsummarytablesenglandandw 
ales/2015-07-15) 
Pre-eclampsia prevalence from NICE guidelines "Hypertension in Pregnancy: the management of hypertensive disorders during 
pregnancy”. National Collaborating Centre for Women's and Children's Health. 2010 
Late miscarriage prevalence from Wyatt PR,OwolabiT, Meier C, Huang T.Age-specific risk of fetal loss observed in a second trimester 
serum screening population.Am J Obstet Gynecol 2005;192:240–6 





4.5 : Discussion 
 
4.5.1 : Main Findings 
 
Low maternal serum PAPP-A in the first trimester has an association with adverse 
pregnancy outcomes with a moderate association once levels are <5th centile for 
gestation and a stronger association <1st centile. The predictive values are poor, thus 
although women with a low PAPP-A are at increased risk of an adverse outcome, the 
vast majority of these women will have a normal pregnancy outcome and the 




4.5.2 : Strengths and Limitations 
 
The strength of this review, and consequently the validity of the results and inferences 
made, lie in its methodology. This included complying with recommended techniques 
for quality assessment (57, 67), performing and interpreting meta-analyses and 
reporting of our findings (59, 75). Our search strategies were comprehensive and 
robust, evidenced by Peters test demonstrating no evidence of small study bias. We 
have considered all aspects of test performance and displayed both prognostic and 
predictive ability of the test as well as demonstrating how the test would perform in a 
sample population. 
 
Limitations within the review relate in the first instance to limitations within the 
included studies. There was significant statistical heterogeneity in some analyses which 
could not be accounted for when examining clinical characteristics nor study design 
and 
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was thus unexplained. Within some analyses there was a lack of data and thus for some 
bivariate meta-analysis could not be performed and for others test performance had to 
be assessed from a single study. We recognise that there are other variables that should 
be considered when assessing risk and that for the clinical interpretation we have 
assumed a background prevalence of the adverse outcome. It is not known how risk 
factors in obstetrics interact and how they modify risk in an individual. It is reasonable 
to assume however that in a woman with multiple risk factors e.g. previous SGA baby 
the risk will be higher than those discussed. One limitation in the methodology 
employed is the need to consider PAPP-A as a dichotomous variable i.e. categorisation 
using a threshold. 
 
This is a common technique in clinical research with dichotomization to simplify the 
analysis. This has limitations statistically as it can lead to a loss of power as much of 
the information is lost, classifying very similar factor values as different in opposite 
sides of the cut-off point and the concealment of a potential non-linear relationship 
between the outcome and the factor of interest (107-109). One technique to overcome 
this is individual patient data meta-analysis (IPD) which uses original source data at the 
participant level thus having many advantages such as being able to derive prognostic 
factor results directly, independent of study reporting and significance, and analyse 




4.5.3 : Interpretation 
 
Prognostic factor research is important as it allows us to potentially improve 
outcome for patients by identifying modifiable factors by either intervention e.g. 
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delivery or by different management pathways e.g. surveillance. If treatments are 
available that may modify disease then prognostic factors may have a role in 
predicting differential treatment response (112). Even if a prognostic factor is 
insufficient as a stand-alone test, it may still add some independent prognostic value 
over other prognostic factors, and used in a multivariable prognostic model to help 
provide absolute risk predictions for women based on their individual characteristics 
(112). It is thus imperative to robustly and systematically assess prognostic factors 




Our results demonstrate evidence of associations between PAPP-A and adverse 
pregnancy outcome. Future work should thus include IPD meta-analysis as previously 
discussed to allow assessment of PAPP-A as a continuous variable and its relationship 
with other prognostic markers available during the pregnancy; first trimester (e.g. 
crown rump length, nuchal translucency), second trimester (e.g. fetal biometry, uterine 
artery Doppler) and third trimester (e.g. placental biomarkers, placental morphology) 
(113-117). Any prognostic model developed would then require validation in external 






Low maternal serum PAPP-A in the first trimester has an association with adverse 
pregnancy outcome particularly if levels are very low (<1st centile). National guidelines 
have identified this evidence and suggested increased surveillance for impaired fetal 
growth (4) but there are no recommendations for surveillance for other adverse  
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outcomes e.g. miscarriage, preterm birth, pre-eclampsia nor for interventions due to the 
increased risk of stillbirth (e.g. induction at term). It must be recognised that for the 
individual predictive value are poor and thus the majority of adverse outcomes will 
occur in the group without an abnormally low PAPP-A and thus outside any guidelines 
for increased surveillance or intervention. Thus, future research is required to develop 
robust and accurate prediction models that can allow modern day obstetrics to practice 
truly stratified medicine (119). 
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CHAPTER 5: Association of maternal serum PAPP-A levels, 
nuchal translucency and crown rump length in first trimester 







Adverse pregnancy outcomes have a considerable psychological impact for the family 
as well as an increased cost of healthcare. Methods of prediction of such events would 
allow obstetricians to provide increased obstetric surveillance, focusing optimum 
management and possibly improving the outcome of the pregnancy. 
 
 
Pregnancy associated plasma protein A (PAPP-A) is a placental glycoprotein produced 
by syncytial trophoblast of the placenta, which cleaves insulin-like growth factor 
binding protein 4 (IGFBP4) and is a positive regulator of insulin-like growth factors 
(IGFs), potentially influencing fetal growth and wellbeing (53). 
 
 
Studies have tested the hypothesis that low maternal serum levels of PAPP-A in the first 
trimester can predict adverse pregnancy outcomes associated with poor placental 
function (5, 6, 49-51). International Guidelines on “The Investigation and Management 
of the Small for Gestational Fetus” have recommended that pregnant women with a 
serum PAPP-A <0.4MoM (1st centile) in the first trimester receive increased ultrasound 
surveillance for fetal growth disorders (4).  However, contradictory results have been 
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observed in publications (51, 120) and few studies have investigated the association of 
first trimester fetal biometry [nuchal translucency (NT) and crown rump length (CRL)] 
with adverse outcomes and their relationship with PAPP-A (5, 52). The objective of 
this study is to determine the relationship between serum pregnancy-associated plasma 
protein-A (PAPP-A), nuchal translucency (NT) and crown rump length (CRL) in first 






5.2.1 Data collection 
 
In this retrospective cohort study, data were collected from patients booked from 1st 
August 2011 (commencement of electronic maternity record) to 31st March 2015 at the 
Birmingham Women’s Foundation Trust (BWNFT), a secondary and tertiary care NHS 
hospital in West Midlands, UK. 
 
 
An ethical committee approval was applied using the online IRAS (integrated research 
application system) application form and emailing the confidentiality advisory group. 





All pregnant women who accepted first trimester aneuploidy screening and delivered in 
BWNFT were included in the study. First trimester aneuploidy screening is offered to 
all pregnant women between 11+2 to 14+1 weeks of gestation (crown–rump length 
measures from 45 mm to 84 mm) as part of the National Downs Syndrome Screening 
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Programme (27, 34). This involves measuring maternal serum levels of PAPP-A and 
free beta human chorionic gonadotrophin (free B HCG), along with the NT, and the 
pregnancy is dated based on CRL. All first trimester scans and measurements 
performed at BWNFT are performed by accredited sonographers as per National 
NEQAS guidelines. Analysis for PAPP-A was performed on the Auto-Delfia 
immunoassay platform (Perkin Elmer Ltd, Seer Green, UK). For the purpose of Down’s 
syndrome screening, PAPP-A values are converted to multiples of the median for 
gestation. To prevent any loss of data and to remove the need for considering an 
absolute threshold, in this study PAPP-A values were considered as a continuous 




The data was collected from the following hospital-based, secure and confidential 
computerized databases. These databases along with the subject demographics, captured 
the following information: 
1. K2 database: Recorded the peri- partum events. 
 
2. Biochemistry database: Recorded of the serum PAPP- A levels, NT and CRL 
along with the gestational age and number of fetuses in the pregnancy. It also 
noted if the pregnancy was result of a donor egg. 





The data from databases was exported in to respective Microsoft Excel formats. 
Subject’s hospital number was used as a common denominator linking all the databases. 
Where available, date of birth and/or NHS number was used for cross referencing. 
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All the excel spread sheets were merged by using ‘merge the tables’ software from Able 
bits excel software support website (121). 
The Biochemistry and K2 databases were merged first. Maternal Hospital numbers 
were used as common denominators to merge the two excel spread sheets. It was cross 
referenced by baby’s date of birth and Maternal NHS number. K2 data was captured 
from 1st August 2011 to 31st March 2015 and biochemistry data was collected from 




Patients having multiple pregnancy with in the study period were highlighted. 
 
Mismatching duplicates were manually checked and removed using baby date of birth 
and date of PAPP-A test.  Pregnancies by donor egg were removed as details such as 
mother’s age were details of the donor, not the carrier. To this data the genetics data 
was linked up and all the patients who had had abnormal karyotypes were highlighted 




Thus, the master sheet containing the data from all different databases was created 
and finally the data was anonymised by assigning research number to each patient in 
place of hospital number and NHS number. 
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5.2.2 Definitions of maternal and obstetric characteristics 
 
Preterm birth (PTB) was defined as live delivery prior to 37 weeks, both spontaneous 
and iatrogenic. Pre-eclampsia (PE) was defined according to the International Society 
for the study of Hypertension in Pregnancy (ISSHP) definition as de-novo hypertension 
at or after 20 weeks gestation (at least 2 readings of Blood Pressure >140 mmHg 
systolic or >90 mmHg diastolic) with proteinuria (spot urine protein/creatinine >30 
mg/mmol [0.3 mg/mg] or >300 mg/day or at least 1 g/L [‘2 +’] on dipstick testing)(57). 
Small for gestational age (SGA) was defined as birthweight below the 10th percentile of 
the customised growth chart (121). Miscarriage was defined as fetal demise before 24 
weeks of gestation. Stillbirth was defined as intrauterine death after 24 completed weeks 
of pregnancy. Perinatal death was defined as fetal or neonatal death between 24 weeks 
of gestation and 7 days after birth. Neonatal death was defined as death between birth 




5.2.3 Data Analysis 
 
5.2.3a Mother and fetus demographics and clinical features 
 
Distributions of demographic characteristics and known prognostic factors were 
summarised for the following variables: maternal age at test, gestational age at test, 
parity, body mass index (BMI), deprivation category (Index of Multiple Deprivation 
2010– IMD (122), calculated using National Perinatal Epidemiology Unit calculator), 
ethnicity, assisted conception (IVF), smoking status, pre-pregnancy insulin-dependent 
diabetes mellitus, and gender of the baby. Mean and standard deviation (SD), or median 
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and interquartile range (IQR), is reported for continuous variables, according to whether 





5.2.3b Analysis of prognostic association with outcomes 
 
Univariable logistic regression analysis was used to estimate the unadjusted odds ratio 
(OR) for each potential prognostic factor (PAPP-A/NT/CRL) separately. The odds 
ratios indicate how much the odds of the outcome are increased for each 1-unit increase 




Again, for each of the three factors separately, multivariable logistic regression 
analyses were fitted to examine the odds ratio adjusted for the known (or likely) 
existing prognostic factors of maternal age (years), parity, BMI, smoking status, IVF, 
ethnicity, deprivation category and gestational diabetes. This provided the adjusted 
odds ratio for a 1-unit increase in each factor, to reveal their independent prognostic 




Then, for each outcome, the three factors were analysed in combination in one 
multivariable logistic regression model, whilst adjusting for the other factors detailed 
above, to explore whether the prognostic value of each factor is the same after adjusting 
for the other two potential prognostic factors. The linearity assumption of all continuous 
variables was assumed for these multivariable models. 
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Therefore, finally, the fully adjusted models with all three potential factors in 
combination were fitted again; however, additionally, the linearity assumption of the 
prognostic effects for the three factors of interest was assessed, and alternative 
functional forms were considered if the assumption was violated. A linear 
relationship was specified for all three prognostic factors of interest. The functional 
form was chosen using fractional polynomials, where all possible fractional 
polynomials up to the second degree were considered based on their statistical 
significance (123). A linear relationship was specified for the other continuous 




In all multivariable models described above, no model selection process was used to 





5.2.3c Handling of missing data 
 
The percentages of missing values for each covariate and outcome were calculated. 
Missing data was imputed with multiple imputation with chained equations with 35 
imputed datasets equal to the percentage of missing data(124). For non-normally 
distributed variables, predictive mean matching was used to impute the missing data 
(125, 126). The imputation model contained all complete outcomes and covariates that 
were included in the multivariable analyses. Rubin’s rules were used to combine the 
57  
parameter estimates and standard errors into a single inference (126). A complete-case 
analysis was also conducted as a sensitivity analysis. 
 
Estimates of prognostic effects are reported as odds ratios (OR) with 95% confidence 






Total number of women delivered in this time frame was 30,099 (as recorded in K2 
software). Biochemistry data from first trimester serum PAPP-A levels was captured 
from 1st January 2011 to 10th October 2014. This had PAPP-A levels for 14352 women. 
After combining K2 data and the biochemistry data we had 12837 women who had 
PAPP-A levels done and their pregnancy outcome was recorded. This difference of 
1515 women could be attributed to the patient flow from and to other hospitals for 
delivery. Ten pregnancies conceived with donor eggs were excluded. Three pregnancies 
with an unclear pregnancy outcome showing death of the babies post 28 days were 
excluded since this outcome would not be routinely recorded in the databases. After 
excluding 232 multiple pregnancies, the final study cohort was of 12,592 singleton 










Table 3: Mother and fetus demographics and clinical features at the test 
 
 Summary (N=12,592) 
Mother’s age (years) 30.6 (5.6) 
Gestational age at test (days) 88.2 (4.3) 
Parity (number) 1 [0,1] 
BMI 25.1 [22.4, 28.8] 
Deprivation score*, n (%) 
≤8.49 455 (3.6) 
8.5 – 13.79 846 (6.7) 
13.8 – 21.35 2629 (20.9) 
21.36 – 34.17 2992 (23.8) 
≥34.18 5495 (43.6) 
Missing 175 (1.4) 
Ethnicity, n (%) 
African-Caribbean 944 (7.5) 
South-Asian 2502 (19.9) 
Oriental 358 (2.8) 
Other mixed 898 (7.1) 
White 7879 (62.6) 
Not stated 11 (0.1) 
Assisted conception, n (%) 250 (2.0) 
Smoking status, n (%) 
Smoker 1569 (12.4) 




Pre-pregnancy insulin-dependent  
Diabetes mellitus, n (%) 
36 (0.3) 
Gender of baby, n (%) 
Male 6118 (48.6) 
Female 6435 (51.1) 
Missing 39 (0.3) 
Mean (standard deviation) or median [interquartile range] for continuous variables and n 
(%) for categorical variables; * Deprivation score calculated using the National Perinatal 




As depicted in Table 3, the mean maternal age and median BMI were 30.6 (SD 5.6) and 
 
25.1 (IQR 22.4 to 28.8), respectively. Majority of the women were White (62.6%) 
followed by South Asians (19.9%). Mean gestational age at first trimester ultrasound 
was 88.2 days (SD 4.3). About 2% (n=250) of pregnancies were the result of assisted 
conception. About 13% (n=1569) women were smokers and about 84% (n=10611) 
women did not smoke while about 3% (n= 412) women stopped smoking during 
pregnancy. Nearly half (43%, n=5495) patients lived in the most deprived areas 
(deprivation score ≥ 34.18) and 3.6% (n=455) patients lived in the least deprived 
areas (deprivation score ≤ 8.49). Gender distribution was almost equal in the fetuses 
(48.6% male and 51.1% female). 
 
 
Table 4: Number of events for each outcome in singleton pregnancies N=12,592 
 
 Number of events (%) 
Pre-term labour (<37 weeks) 852 (6.77) 
 Pre-eclampsia 352 (2.80) 
SGA (<10th customised centile) 1824 (14.49) 
Miscarriage (death prior to birth <24 weeks gestation) 73 (0.58) 
Stillbirth (death prior to birth >24 weeks gestation) 37 (0.29) 
Perinatal death* (Death between 24 weeks gestation 
and 7 days after birth) 
 
73 (0.58) 
Neonatal death$ (Death between birth and 28 days) 38 (0.31) 
* Perinatal death includes stillbirths; $ neonatal death includes babies that die between 












Table 4 displays the number of events for each outcome for the cohort. Of 12592 
women, 852 had preterm birth (6.8%). This compares lower than the national rate of 
about 11%) (128). 352 patients had pre-eclampsia ( both mild and severe ) (2.8%). This 
is comparable with the national rates of about 2 % for severe pre eclampsia and about  
6 %  for mild pre eclampsia (129).  1824 babies were SGA (14.5%) which is higher 
than expected (> 10 %) of the cohort. There were 73 pregnancies that ended in 
miscarriage (0.6%)and 37 stillbirths (0.3%)which is lower than national rate of 0.5% 
(130). There were 38 neonatal deaths (0.31%) of which 36 were early and thus giving a 
total of 73 perinatal deaths (0.6%). 
 
 
Table 5: Number and percentage of missing covariate data for singleton 
pregnancies 
 
 n (%) missing data 
PAPP-A (U/L) 0 (0) 
Nuchal translucency (mm) 2 (0.02) 
Crown rump length (mm) 2 (0.02) 
Mother’s age (years) 0 (0) 
Gestational age at birth (days) 0 (0) 
Parity (number) 567 (4.5) 
BMI 4466 (35.5) 
Deprivation score* 175 (1.4) 
Ethnicity 0 (0) 
Assisted conception 0 (0) 
Smoking status 0 (0) 







BMI was missing in 4466 (35.5%) records, parity was missing in 567 (4.5%) records 
and deprivation score was missing in 175 (1.4%) records. There were missing data for 
152 (1.2%) fetal weight and four (0.03 %) neonatal outcomes (table 5). Multiple 
imputation was performed for missing BMI (height, weight), parity and deprivation  
score values. Although some variables were normally distributed, predictive mean 
matching was used for all variables because imputation with chained regression 




5.3.1 PAPP-A results 
 










SGA 0.874 0.849 to 0.900 <0.0001 
Pre-term labour 0.934 0.899 to 0.970 <0.0001 
Pre-eclampsia 0.915 0.862 to 0.971 0.004 
Miscarriage 0.968 0.858 to 1.092 0.598 
Stillbirth 0.810 0.655 to 1.002 0.052 
Perinatal death 0.927 0.815 to 1.054 0.245 






An unadjusted OR for PAPP-A for the outcome of SGA means that for a one unit 
increase in PAPP-A (U/L), the odds are lower by 13% (table 6). This is a highly 
statistically significant result with a 95% CI that suggests there is between 10.0% and a 
15.1% lower odds of SGA for a one unit increase in PAPP-A (p<0.0001). Similar 
conclusions can be drawn for the association between PAPP-A   and pre-term birth 
[OR 0.93 (95%CI 0.90, 0.97), p<0.0001]. In addition, PAPP-A and pre-eclampsia 
demonstrated a similar relationship [OR 0.92 (95% CI 0.86, 0.97), p=0.004]. The 
results for stillbirth were in the same direction and quantitatively similar, although the 
CI was slightly wider and the p-value was just above the 5% [OR 0.81 (95% CI 0.66, 
1.0), p=0.052]. There was no evidence of a strong association between PAPP-A and 
miscarriage, perinatal death or neonatal death. 
Multivariable analysis was performed after adjusting for mother’s age, BMI, 
parity, ethnicity, deprivation score, smoking status, IVF status, and gestational 
diabetes. 


























PAPP-A (U/L) 0.878 0.851 to 0.906 <0.0001 
Mother’s age (years) 1.016 1.005 to 1.026 0.003 
BMI 1.000 0.988 to 1.012 0.996 
Parity 
0 1.178 1.054 to 1.316 0.004 
>4 1.015 0.627 to 1.644 0.952 
Ethnicity 
South-Asian 0.764 0.616 to 0.947 0.014 
Oriental 0.695 0.529 to 0.896 0.006 
Other Mixed 0.689 0.529 to 0.896 0.006 
White 0.650 0.535 to 0.792 <0.0001 
Deprivation 
score categories 
2 1.120 0.790 to 1.590 0.524 
3 1.033 0.758 to 1.406 0.838 
4 1.037 0.763 to 1.410 0.817 
5 1.120 0.884 to 1.616 0.245 
Smoking status 
Yes 2.547 2.218 to 2.926 <0.0001 
Stopped 1.153 0.870 to 1.534 0.327 
IVF 0.661 0.432 to 1.011 0.056 
Gestational diabetes 0.987 0.780 to 1.219 0.903 
N=12,300 
 
In this adjusted analysis in Table 7, there is evidence of an association between PAPP- 
A and SGA with an odds ratio estimate of 0.87. The estimate is statistically significant 
with a 95% confidence interval of 0.85 to 0.90, suggesting between 10% and 15% lower 
odds of SGA (p<0.0001) for a one unit increase in PAPP-A, having adjusted for 




Table 8: PAPP-A: Results from adjusted logistic regression for preterm birth(<37 
weeks, N=12,454) 
 







PAPP-A (U/L) 0.924 0.884 to 0.965 <0.0001 
Mother’s age (years) 1.001 0.995 to 1.024 0.215 
BMI 0.995 0.978 to 1.012 0.568 
Parity 
0 1.027         0.872 to 1.211 0.747 
>4 1.015 0.627 to 1.644 0.952 
Ethnicity 
South-Asian 0.683 0.508 to 0.918 0.011 
Oriental 0.409 0.222 to 0.752 0.004 
Other Mixed 0.665 0.461 to 0.960 0.029 
White 0.624 0.478 to 0.816 0.001 
Deprivation 
score categories 
2 0.866 0.526 to 1.424 0.571 
3 0.874 0.570 to 1.339 0.536 
4 0.921 0.603 to 1.405 0.702 
5 1.065 0.704 to 1.611 0.765 
Smoking status 
Yes 1.641 1.333 to 2.021 <0.0001 
Stopped 0.907 0.578 to 1.422 0.670 
IVF 1.083 0.642 to 1.828 0.764 




Table 8 showing adjusted analysis, there is evidence of lower odds of a preterm birth 
as PAPP-A increases with an odds ratio estimate of 0.92. The estimate is statistically 




10% lower odds of preterm birth (p=0.001) for a one unit increase in PAPP-A, having 
adjusted for mother’s age, BMI, parity, ethnicity, deprivation score, smoking status, 
IVF status, and gestational diabetes. 
 









PAPP-A (U/L) 0.906 0.848 to 0.968 0.003 
Mother’s age (years) 1.015 0.993 to 1.037 0.185 
BMI 1.046 1.022 to 1.070 <0.0001 
Parity 
0 2.634 2.059 to 3.369 <0.0001 
>4 1.000 - - 
Ethnicity 
South-Asian 0.569 0.378 to 0.857 0.007 
Oriental 0.282 0.109 to 0.729 0.009 
Other Mixed 0.441 0.252 to 0.773 0.004 
White 0.519 0.360 to 0.748 <0.0001 
Deprivation 
score categories 
2 0.700 0.371 to 1.320 0.270 
3 0.718 0.421 to 1.224 0.223 
4 0.625 0.365 to 1.068 0.086 
5 0.824 0.491 to 1.384 0.464 
Smoking status 
Yes 0.573 0.371 to 0.886 0.012 
Stopped 0.941 0.520 to 1.702 0.841 
IVF 1.662 0.954 to 2.896 0.073 











Where the odds ratios are omitted in results tables, there were no events for the 
categories amongst those individuals included in the analysis. In this analysis in table 7, 
there was no estimate of an odds ratio for parity >4 compared to parity of 1-4 because 
there were no events of pre-eclampsia toxaemia for those that have a parity >4. 
In this adjusted analysis, there is evidence of lower odds of a pre-eclampsia as PAPP- 
A increases with an odds ratio estimate of 0.908 (table 9). The estimate is statistically 
significant with a 95% confidence interval of 0.85 to 0.97, suggesting between 3% and 
15% lower odds of pre-eclampsia (p=0.004) for a one unit increase in PAPP-A, having 
adjusted for mother’s age, BMI, parity, ethnicity, deprivation score, smoking status, IVF 
status, and gestational diabetes. 
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Table 10: PAPP-A: Results from adjusted logistic regression for miscarriage (<24 
weeks gestation, N=10,404) 
 




95% Confidence Interval OR p-value 
PAPP-A (U/L) 1.008 0.839 to 1.212 0.929 
Mother’s age (years) 0.966 0.903 to 1.033 0.315 
BMI 1.045 0.985 to 1.111 0.146 
Parity 
0 0.538 0.253 to 1.144 0.108 
>4 1.000 - - 
Ethnicity 
South-Asian 1.404 0.364 to 5.411 0.622 
Oriental 1.000 - - 
Other Mixed 1.608 0.351 to 7.363 0.541 
White 0.896 0.250 to 3.210 0.866 
Deprivation 
score categories 
2 1.000 - - 
3 0.845 0.098 to 7.302 0.878 
4 1.734 0.221 to 13.586 0.600 
5 1.207 0.154 to 9.451 0.858 
Smoking status 
Yes 0.762 0.255 to 2.277 0.626 
Stopped 0.821 0.110 to 6.123 0.848 
IVF 2.230 0.288 to 17.294 0.443 




In this adjusted analysis in table 10, there is no evidence of an association between 
miscarriage and PAPP-A after adjusted for the other factors since the odds ratio 




Table 11: PAPP-A: Results from adjusted logistic regression for stillbirth (>24 
weeks gestation) (singleton pregnancies, N =9,753) 
 




95% Confidence Interval OR p-value 
PAPP-A (U/L) 0.714 0.520 to 0.981 0.038 
Mother’s age (years) 0.983 0.904 to 1.069 0.693 
BMI 1.003 0.925 to 1.087 0.945 
Parity 
0 1.983 0.825 to 4.769 0.126 
>4 1.000 - - 
Ethnicity 
South-Asian 1.998 0.239 to 16.710 0.523 
Oriental 1.000 - - 
Other Mixed 0.867 0.053 to 14.112 0.920 
White 1.227 0.154 to 9.765 0.847 
Deprivation 
score categories 
2 0.540 0.067 to 4.351 0.562 
3 1.099 0.382 to 3.162 0.861 
4 0.964 0.342 to 2.715 0.944 
5 1.000 - - 
Smoking status 
Yes 1.000 - - 
Stopped 0.992 0.131 to 7.512 0.994 
IVF 1.000 - - 
Gestational diabetes 1.000 - - 
N=9,75
In Table 11, there is evidence of lower odds of a stillbirth as PAPP-A increases with an 
odds ratio estimate of 0.723. The estimate is statistically significant with a 95% 
confidence interval of 0.53 to 0.99, suggesting between 1% and 47% lower odds of 
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stillbirth (p=0.044) for a one unit increase in PAPP-A, having adjusted for mother’s age, 
BMI, parity, ethnicity, deprivation score, smoking status, IVF status, and gestational 
diabetes. 
Table 12: PAPP-A: Results from adjusted logistic regression for perinatal death 
(death between 24 weeks gestation and 7 days after birth) (singleton pregnancies, 
N=10,898) 
 
Perinatal death (death between 







PAPP-A (U/L) 0.880 0.733 to 1.058 0.173 
Mother’s age (years) 0.961 0.903 to 1.023 0.211 
BMI 1.063 1.010 to 1.118 0.020 
Parity 
0 2.246 1.166 to 4.328 0.016 
>4 1.000 - - 
Ethnicity 
South-Asian 0.567 0.218 to 1.454 0.236 
Oriental 0.369 0.044 to 3.077 0.357 
Other Mixed 0.345 0.089 to 1.338 0.124 
White 0.219 0.089 to 0.538 0.001 
Deprivation 
score categories 
2 2.279 0.812 to 6.394 0.118 
3 0.967 0.395 to 2.369 0.942 
4 1.184 0.556 to 2.518 0.662 
5 1.000 - - 
Smoking status 
Yes 0.830 0.280 to 2.454 0.736 
Stopped 1.375 0.323 to 5.845 0.667 
IVF 1.000 - - 
Gestational diabetes 1.000 - - 
N=10,898
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Table 12 shows there is no evidence of an association between perinatal death and 
PAPP-A after adjusting for the other factors since the odds ratio estimate is 0.88 
(95% CI: 0.73 to 1.05; p=0.164). 
Table 13: PAPP-A: Results from adjusted logistic regression for neonatal death 
(death between birth and 28 days after birth) (singleton pregnancies, N=10,876) 
 
Neonatal death (death between 






PAPP-A (U/L) 1.043 0.847 to 1.287 0.687 
Mother’s age (years) 0.949 0.865 to 1.040 0.261 
BMI 1.122 1.051 to 1.198 0.001 
Parity 
0 2.360 0.8908 to 6.132 0.078 
>4 1.000 - - 
Ethnicity 
South-Asian 0.464 0.139 to 1.555 0.213 
Oriental 0.659 0.073 to 5.956 0.711 
Other Mixed 0.267 0.052 to 1.371 0.114 
White 0.069 0.019 to 0.246 <0.0001 
Deprivation 
score categories 
2 5.652 1.607 to 19.884 0.007 
3 0.384 0.048 to 3.078 0.368 
4 1.241 0.420 to 3.663 0.696 
5 1.000 - - 
Smoking status 
Yes 3.041 0.895 to 10.329 0.075 
Stopped 2.271 0.284 to 18.145 0.439 
IVF 1.000 - - 








Table 13 shows there is no evidence of an association between neonatal death and 
PAPP-A after adjusted for the other factors since the odds ratio estimate is 1.03 (95% 
CI: 0.83 to 1.27; p=0.786). 




In both the unadjusted analyses and the adjusted analyses, there is significant evidence 
of lower odds of SGA, premature labour, pre-eclampsia and stillbirth as PAPP-A 
increases. There is no evidence of a significant association between PAPP-A and 
miscarriage, perinatal death or neonatal death. 
 
5.3.2 NT result 
 
Similar analysis was carried out looking for relation of NT and CRL with adverse 
pregnancy outcomes. Detailed analysis and the tables can be found in appendices 11 and 
12. Summary of the analysis is as below: 
 
For NT, in the unadjusted analyses (Appendix 11: Table 14a), for higher values of NT 
there was a strong association with an increased odds of miscarriage [OR 1.94 (95% CI 
1.54, 2.45), p<0.0001], and a significant decreased odds of SGA [OR 0.81 (95% CI 
0.72, 0.91), p<0.0001]. There was also some evidence that higher values are associated 
with an increased risk of PTB [OR 1.15 (95% CI 1.0, 1.32), p=0.053] though the CI 
overlapped one. 
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After multivariable analysis, there was independent prognostic value of NT for SGA 
[OR 0.8 (95% CI 0.71, 0.90), p<0.001] (Appendix 11 Table 14b), and for miscarriage 
[OR 1.75 (95% CI 1.12, 2.72), p=0.013] (Appendix 11: Table 14e). There was no 
significant relationship between NT and PTB, PE, stillbirth, perinatal or neonatal death 




5.3.3 CRL Results 
 
For CRL in the unadjusted analysis there was no significant association with any of the 
outcomes (Appendix 12: Table 15a). There was a borderline statistical significance for 
SGA which remained after adjustment [OR 0.99 (95% CI 0.99, 1.00, p=0.051)] 
(Appendix 12: Table 15b), but the magnitude of the OR was close to one. After 
adjustment for other known predictors and potential confounders, there was evidence of 
a strong association between CRL and stillbirth [OR 0.94 (95% CI 0.89, 0.99), 
p=0.027], thus between 1% and 11% lower odds of stillbirth for a one unit increase in 
CRL (Appendix 12: Table 15f). The adjusted analyses for PTB, PE, miscarriage, 
perinatal death and neonatal death demonstrated no significant association with CRL 
(Appendix 12: Tables 15-c,d,e,g,h). 
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5.3.4 Adjustment for all three potential prognostic factors 
 
 
Finally, the fully adjusted models with all three potential factors in combination 
were fitted again. The results are as follows. 
 
In the adjusted analysis shown in Table 16a, the odds of SGA are statistically 
significantly lower as PAPP-A and NT increase, with odds ratio estimates of 0.86 (95% 
CI: 0.83 to 0.89; p<0.0001), and 0.80 (95% CI: 0.70 to 0.92; p=0.001), respectively. 
The odds of SGA are also statistically significantly higher as CRL increases with an 
odds ratio estimate of 1.01 (95% CI: 1.00 to 1.02; p=0.003). 
 
In adjusted analysis in Table 16b, the odds of preterm birth are statistically 
significantly lower as PAPP-A increases, with an odds ratio estimates of 0.91 (95% CI: 
0.87 to 0.95; p<0.0001). The association between NT and preterm birth and 
between CRL and preterm birth are not statistically significant (similar to the 
analyses without the other two potential prognostic markers). 
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Table 16 a: PAPP-A, NT and CRL: Results from adjusted logistic regression for 
SGA (singleton pregnancies, N=12,299) 
SGA (<10
th






PAPP-A (U/L) 0.869 0.839 to 0.899 <0.0001 
NT (mm) 0.795 0.696 to 0.909 0.001 
CRL (mm) 1.011 1.003 to 1.018 0.004 
Mother’s age (years) 1.015 1.005 to 1.026 0.003 
BMI 0.999 0.987 to 1.012 0.922 
Parity 
0 1.178 1.054 to 1.316 0.004 
>4 1.026 0.633 to 1.661 0.918 
Ethnicity 
South-Asian 0.762 0.614 to 0.945 0.013 
Oriental 0.709 0.491 to 1.024 0.067 
Other Mixed 0.686 0.527 to 0.893 0.005 
White 0.651 0.535 to 0.792 <0.0001 
Deprivation score 
categories 
2 1.124 0.792 to 1.594 0.512 
3 1.024 0.752 to 1.394 0.882 
4 1.031 0.758 to 1.402 0.845 
5 1.192 0.882 to 1.611 0.253 
Smoking status 
Yes 2.542 2.212 to 2.921 <0.0001 
Stopped 1.158 0.870 to 1.541 0.314 
IVF 0.656 0.429 to 1.003 0.052 










Table 16b: PAPP-A, NT and CRL: Results from adjusted logistic regression for 
preterm birth (singleton pregnancies, N=12,453) 







PAPP-A (U/L) 0.915 0.872 to 0.960 <0.0001 
NT (mm) 1.124 0.946 to 1.335 0.183 
CRL (mm) 1.003 0.992 to 1.013 0.632 
Mother’s age (years) 1.009 0.994 to 1.024 0.232 
BMI 0.993 0.976 to 1.011 0.444 
Parity 
0 1.033 0.876 to 1.219 0.694 
>4 0.982 0.489 to 1.974 0.960 
Ethnicity 
South-Asian 0.675 0.502 to 0.908 0.009 
Oriental 0.398 0.216 to 0.732 0.003 
Other Mixed 0.658 0.456 to 0.950 0.025 
White 0.615 0.470 to 0.804 <0.0001 
Deprivation 
score categories 
2 0.868 0.528 to 1.428 0.578 
3 0.872 0.569 to 1.336 0.528 
4 0.924 0.605 to 1.410 0.712 
5 1.067 0.706 to 1.614 0.758 
Smoking status 
Yes 1.618 1.313 to 1.993 <0.0001 
Stopped 0.899 0.523 to 1.410 0.642 
IVF 1.070 0.634 to 1.807 0.800 











In adjusted analysis as seen in Table 16c, the odds of pre-eclampsia are statistically 
significantly lower as PAPP-A increases and statistically significantly lower as CRL 
increases, with odds ratio estimates of 0.88 (95% CI: 0.82 to 0.95; p=0.001), and 1.02 
(95% CI: 1.01 to 1.04; p=0.006), respectively. There is no association between pre- 




In this adjusted analysis (Table 16d), the odds of miscarriage are statistically 
significantly higher as NT increases, with an odds ratio estimates of 1.67 (95% CI: 1.01 
to 2.76; p=0.047). The association between PAPP-A and miscarriage and also between 
CRL and miscarriage are not statistically significant (similar to the analyses without the 
other two potential prognostic markers). 
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Table 16c: PAPP-A, NT and CRL: Results from adjusted logistic regression for pre- 








PAPP-A (U/L) 0.876 0.815 to 0.942 <0.0001 
NT (mm) 0.782 0.584 to 1.046 0.097 
CRL (mm) 1.023 1.007 to 1.039 0.004 
Mother’s age (years) 1.013 0.992 to 1.035 0.239 
BMI 1.043 1.019 to 1.067 <0.0001 
Parity 
0 2.641 2.065 to 3.378 <0.0001 
>4 1.000 - - 
Ethnicity 
South-Asian 0.561 0.375 to 0.845 0.006 
Oriental 0.286 0.111 to 0.740 0.010 
Other Mixed 0.435 0.248 to 0.763 0.004 
White 0.512 0.355 to 0.739 <0.0001 
Deprivation 
score categories 
2 0.709 0.375 to 1.337 0.288 
3 0.715 0.419 to 1.220 0.218 
4 0.623 0.364 to 1.065 0.084 
5 0.818 0.487 to 1.374 0.448 
Smoking status 
Yes 0.568 0.367 to 0.878 0.011 
Stopped 0.938 0.518 to 1.697 0.832 
IVF 1.605 0.921 to 2.798 0.095 




Table 16d: PAPP-A, NT and CRL: Results from adjusted logistic regression for 
miscarriage (singleton pregnancies, N=10,404) 
 







PAPP-A (U/L) 0.945 0.771 to 1.159 0.588 
NT (mm) 1.669 1.007 to 2.764 0.047 
CRL (mm) 1.024 0.980 to 1.070 0.285 
Mother’s age (years) 0.963 0.900 to 1.030 0.272 
BMI 1.036 0.974 to 1.102 0.261 
Parity 
0 0.555 0.261 to 1.183 0.127 
>4 1.000 - - 
Ethnicity 
South-Asian 1.287 0.337 to 4.963 0.714 
Oriental 1.000 - - 
Other Mixed 1.459 0.317 to 6.713 0.627 
White 0.801 0.223 to 2.879 0.734 
Deprivation 
score categories 
2 1.000 - - 
3 0.866 0.100 to 7.500 0.896 
4 1.758 0.224 to 13.783 0.591 
5 1.187 0.151 to 9.308 0.870 
Smoking status 
Yes 0.725 0.242 to 2.175 0.566 
Stopped 0.756 0.101 to 5.662 0.785 
IVF 2.046 0.262 to 15.958 0.494 








Table 16e: PAPP-A, NT and CRL: Results from adjusted logistic regression for 
stillbirth (singleton pregnancies, n=9,753) 
 







PAPP-A (U/L) 0.785 0.563 to 1.093 0.152 
NT (mm) 1.191 0.447 to 3.176 0.726 
CRL (mm) 0.953 0.894 to 1.016 0.142 
Mother’s age (years) 0.988 0.910 to 1.075 0.787 
BMI 1.011 0.933 to 1.096 0.787 
Parity 
0 1.968 0.816 to 4.743 0.132 
>4 1.000 - - 
Ethnicity 
South-Asian 2.039 0.243 to 17.087 0.511 
Oriental 1.000 - - 
Other Mixed 0.903 0.055 to 14.698 0.943 
White 1.268 0.159 to 10.117 0.823 
Deprivation 
score categories 
2 0.517 0.064 to 4.172 0.536 
3 1.092 0.380 to 3.140 0.870 
4 0.961 0.341 to 2.704 0.940 
5 1.000 - - 
Smoking status 
Yes 1.000 - - 
Stopped 1.030 0.136 to 7.808 0.977 
IVF 1.000 - - 





















There is no statistically significant evidence of associations between PAPP-A, NT or 
CRL and stillbirth after adjusting for each other and the other known predictors. 
Table 16f: PAPP-A, NT and CRL: Results from adjusted logistic regression for 
perinatal death (singleton pregnancies, N=10,898) 
 
Perinatal death (death between 







PAPP-A (U/L) 0.921 0.757 to 1.119 0.408 
NT (mm) 1.176 0.565 to 2.448 0.665 
CRL (mm) 0.973 0.931 to 1.017 0.226 
Mother’s age (years) 0.964 0.906 to 1.026 0.247 
BMI 1.070 1.013 to 1.123 0.014 
Parity 
0 2.237 1.159 to 4.315 0.016 
>4 1.000 - - 
Ethnicity 
South-Asian 0.574 0.222 to 1.486 0.253 
Oriental 0.368 0.044 to 3.081 0.357 
Other Mixed 0.355 0.092 to 1.377 0.134 
White 0.224 0.091 to 0.551 0.001 
Deprivation 
score categories 
2 2.214 0.789 to 6.217 0.131 
3 0.961 0.393 to 2.354 0.931 
4 1.170 0.550 to 2.488 0.684 
5 1.000 - - 
Smoking status 
Yes 0.838 0.283 to 2.479 0.749 
Stopped 1.407 0.330 to 5.990 0.644 
IVF 1.000 - - 






There is no statistically significant evidence of associations between PAPP-A, NT or 
CRL and perinatal death after adjusting for each other and the other known predictors. 
 
Table 16g: PAPP-A, NT and CRL: Results from adjusted logistic regression for 
neonatal death (singleton pregnancies, N=10,876) 
 
Neonatal death (death between 






PAPP-A (U/L) 1.059 0.842 to 1.331 0.624 
NT (mm) 1.117 0.377 to 3.312 0.842 
CRL (mm) 0.989 0.931 to 1.052 0.733 
Mother’s age (years) 0.950 0.866 to 1.041 0.270 
BMI 1.124 1.052 to 1.200 0.001 
Parity 
0 2.355 0.906 to 6.123 0.079 
>4 1.000 - - 
Ethnicity 
South-Asian 0.470 0.140 to 1.579 0.222 
Oriental 0.658 0.072 to 5.993 0.711 
Other Mixed 0.271 0.053 to 1.397 0.119 
White 0.069 0.020 to 0.250 <0.0001 
Deprivation 
score categories 
2 5.453 1.550 to 19.187 0.008 
3 0.345 0.043 to 2.757 0.316 
4 1.162 0.394 to 3.427 0.786 
5 1.000 - - 
Smoking status 
Yes 3.044 0.897 to 10.337 0.074 
Stopped 2.294 0.286 to 18.381 0.434 
IVF 1.000 - - 
Gestational diabetes 1.000 - - 
N=10,87
There is no statistically significant evidence of associations between PAPP-A, NT or 
CRL and neonatal death after adjusting for each other and the other known predictors. 
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FUNCTIONAL FORM OF POTENTIAL PROGNOSTIC FACTORS 
Table 16h: PAPP-A, NT and CRL: Results from adjusted logistic regression for 











Loge(PAPP-A) (U/L) 0.636 0.580 to 0.697 <0.0001 
NT (mm) 0.792 0.693 to 0.905 0.001 
CRL (mm) 1.014 1.005 to 1.021 <0.0001 
Mother’s age (years) 1.016 1.005 to 1.026 0.003 
BMI 0.996 0.983 to 1.008 0.487 
Parity 
0 1.187 1.063 to 1.326 0.002 
>4 1.040 0.642 to 1.686 0.873 
Ethnicity 
South-Asian 0.761 0.614 to 0.944 0.013 
Oriental 0.712 0.493 to 1.027 0.069 
Other Mixed 0.687 0.528 to 0.894 0.005 
White 0.646 0.531 to 0.786 <0.0001 
Deprivation score 
categories 
2 1.120 0.789 to 1.589 0.528 
3 1.024 0.751 to 1.395 0.882 
4 1.029 0.756 to 1.399 0.856 
5 1.192 0.881 to 1.612 0.255 
Smoking status 
Yes 2.496 2.171 to 2.869 <0.0001 
Stopped 1.152 0.866 to 1.534 0.331 
IVF 0.648 0.423 to 0.992 0.046 







The log transformation was the statistically best fitting functional form for PAPP-A in 
this analysis in Table 16h. The linear function was selected for nuchal translucency and 





For crown rump length and nuchal translucency the linear function was best. The best 
functional form for PAPP-A was 1/sqrt (PAPP-A). Again, only PAPP-A was 
statistically significantly associated with preterm birth(Table 16i). 
 84  
Table 16i: PAPP-A, NT and CRL: Results from adjusted logistic regression for 
preterm birth assessing functional form of PAPP-A, NT and CRL (singleton 
pregnancies, N=12453) 
 







1/√PAPPA (U/L) 2.329 1.669 to 3.250 <0.0001 
NT (mm) 1.117 0.941 to 1.326 0.204 
CRL (mm) 1.005 0.994 to 1.015 0.386 
Mother’s age (years) 1.009 0.995 to 1.024 0.218 
BMI 0.990 0.973 to 1.008 0.276 
Parity 
0 1.039 0.881 to 1.225 0.648 
>4 0.999 0.497 to 2.009 0.999 
Ethnicity 
South-Asian 0.682 0.509 to 0.914 0.011 
Oriental 0.403 0.219 to 0.741 0.003 
Other Mixed 0.663 0.4650to 0.956 0.028 
White 0.616 0.473 to 0.804 <0.0001 
Deprivation 
score categories 
2 0.862 0.524 to 1.419 0.560 
3 0.871 0.570 to 1.335 0.526 
4 0.920 0.602 to 1.404 0.698 
5 1.063 0.703 to 1.609 0.771 
Smoking status 
Yes 1.589 1.290 to 1.956 <0.0001 
Stopped 0.896 0.571 to 1.406 0.634 
IVF 1.057 0.626 to 1.786 0.835 
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 16j: PAPP-A, NT and CRL: Results from adjusted logistic regression for pre- 





 95% Confidence 
 Ratio Interval OR 
p-value 
PAPP-A (u/l) 0.879 0.817 to 0.945 0.001 
NT (mm) 0.792 0.592 to 1.060 0.117 
CRL (mm) 1.023 1.007 to 1.039 0.006 
Mother’s age (years) 1.013 0.992 to 1.035 0.223 
BMI 1.042 1.017 to 1.067 0.001 
0 2.674 2.099 to 3.407 <0.0001 
Parity    
>4 1.000 - - 
South-    
Asian 
0.557 0.369 to 0.839 0.005 
Oriental 0.288 0.111 to 0.746 0.010 
Ethnicity 
Other 
   
Mixed 
0.403 0.227 to 0.713 0.002 
White 0.494 0.342 to 0.712 0.000 





0.713 0.417 to 1.217 0.215 
categories 4 0.602 0.351 to 1.032 0.065 
5 0.783 0.466 to 1.316 0.356 
Smoking Yes 0.623 0.355 to 1.092 0.099 
status Unknown 1.034 0.828 to 1.292 0.765 
IVF 1.630 0.935 to 2.843 0.085 





5.3.4: PAPP-A, NT and CRL in combination 
 
Assuming linear functions for all continuous variables, the three potential 
prognostic factors were then considered in combination with adjustment for 
confounders and known prognostic factors as discussed (Tables 16a-j). For SGA, this 
analysis demonstrated statistically significant associations with PAPP-A                   
[OR 0.86 (95% CI 0.83, 0.89), p<0.0001)]; NT [OR 0.80 (95% CI 0.70, 0.92); 
p=0.001] and CRL [OR 1.01 (95% CI 1.00, 1.02); p=0.003)] (Table 16h). 
                      
          For preterm birth (Table 16i), only PAPP-A was statistically significantly 
associated with reduced odds [OR 0.91 (95% CI 0.87, 0.95), p<0.0001], as seen when 
the factors were considered individually. For pre-eclampsia, PAPP-A was still 
significantly associated [OR 0.88 (95% CI 0.82, 0.95); p=0.001] and now there was 
evidence of increased odds of pre-eclampsia as CRL increases [OR 1.02 (95% CI 1.01, 




There remained a statistically significantly increased odds of miscarriage as 
NT increases [OR 1.67 (95% CI 1.01, 2.76), p=0.047], and no evidence of 
associations between miscarriage and PAPP-A or CRL (Table 16d). There were no 
statistically significant associations between stillbirth and any of PAPP-A, NT or 
CRL, unlike the individual models (Table 16e). There was no evidence of associations 






After checking the linearity assumption of the three prognostic factors, all the 
associations remained the same. However, the log transformation was statistically the 
best fitting functional form of PAPP-A for SGA, and 1/√PAPP-A was statistically the 
best fitting functional form of PAPP-A for PTB. For PAPP-A for all other outcomes 
and for CRL and NT for all outcomes, the best fitting functional form was the linear 
function. 
5.4 : Discussion 
 
5.4.1 : Main Findings 
 
This large cohort study provides strong evidence that lower values of PAPP-A 
are associated with an increased odds of SGA, stillbirth, PE and PTB. As NT 
increases, there is evidence of a lower odds of SGA but higher odds of miscarriage. As 
CRL decreases there is evidence of higher odds of stillbirth and possibly with SGA. 
Neonatal and perinatal deaths were not associated with any of the prognostic factors 
measured in the first trimester. When considered in combination there is a statistically 
significant association of PAPP-A, NT and CRL with SGA; preterm birth with PAPP-
A, pre- eclampsia with PAPP-A and CRL, and miscarriage with NT. In the combined 
model stillbirth is no longer associated with any of the factors. 
5.4.2 Strengths and Limitations: 
 
Our study has several strengths. This is a large cohort study looking at multiple 
pregnancy outcomes providing reproducible statistical results. The UK is a country 
where high quality and homogenous universal health care is provided to its residents 
free of charge irrespective of socioeconomic and other statuses. This made our cohort a 
reliable  representative of the population avoiding bias due to skewed demographics.  
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Certain factors that are known to affect pregnancy outcome, such as ethnicity, 
parity, maternal age and BMI, socio economic deprivation, smoking status and pre-
pregnancy insulin-dependent diabetes mellitus, have been adjusted for in our analysis. 
We have made an effort to look for lesser researched possible associations such as 
miscarriage and neonatal/perinatal death. Despite these strengths, our study is not 
without limitations. The data for potential confounding factors (existing prognostic 
factors) was limited to that which is routinely collected in our electronic maternity 
record as this was a retrospective study. Although the databases used were not 
designed for this particular study they are populated by qualified health professionals 
and data was obtained from multiple sources to allow cross-referencing and checking 
of outcomes. The biochemistry data is part of the National Screening Programme and 
thus subject to the relevant quality assurance (UK National external quality assurance 
scheme (UKNEQAS), Edinburgh Royal Infirmary, UK and Downs syndrome 
screening quality assurance and support service (DQASS), University of Plymouth 
UK). Our sample was determined by the number of patients available with an 
electronic record and outcome data and thus not determined by a sample size 
calculation. Most confidence intervals were quite narrow, but we recognise that non-
significant findings do not necessarily mean that no prognostic association exists, and 
may simply reflect a low power to detect genuine associations. Nevertheless, many 
confidence intervals were relatively narrow and the prognostic associations identified 
were often strongly significant (131) 
 
The clinical utilisation of CRL as an individual prognostic factor (i,e outside of a model 
using it as a continuous factor) is less clear as standard care in UK is for a single first 
trimester ultrasound to incorporate dating ( using CRL) and NT for aneuploidy risk. 
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Previous studies have assessed the prognostic value of difference in expected to observed 
CRL based on the last menstrual period or observed versus expected change in CRL in 
the first trimester and CRL as a continuous factor in multivariable analysis (52) (132, 
133). The use of CRL to date a pregnancy assumes that there is no growth variation 
within the first trimester nor association with factors such as fetal sex, maternal age 
or ethnicity(133, 134). A study from the Netherlands demonstrated that CRL in the first 
trimester was associated with an increased risk of adverse birth outcomes ad postnatal 
growth acceleration (133). As standard care in the UK is only to offer one first trimester 
ultrasound, thus it is not possible to assess CRL change and the use of the CRL to date 
the pregnancy does not allow the assessment of observed to expected CRL. We thus 
wished to assess whether CRL, measured between the 11+2 to 14+1 week window, 
assessed as a continuous variable had a relationship with adverse pregnancy outcome i.e. 




The aim was to provide more evidence toward establishing if the prognostic factors of 
interest can be used to further inform the management of potential adverse outcomes, 
for example by increased surveillance for pregnant women at greater risk. The results 
showed evidence of associations between the potential prognostic factors and several 
outcomes, and the associations remained largely the same when the factors were 
considered in combination. Future work is now important to establish whether the 
findings from all prognostic factor studies are consistent by synthesizing the 
evidence. The evidence from this study supports the need for women with 
pregnancies with a low PAPP-A and increased NT being under Consultant led care 
and the recommendation within the RCOG guidelines (4) for increased surveillance 
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for SGA in pregnancies with a low PAPP-A and supports this being extended to 
pregnancies in the first trimester with an increased NT. At present until a model is 
developed that can incorporate these factors as continuous variables it would be 
appropriate to use accepted thresholds of<5th centile for PAPP-A and >99th centile 
for NT. Due to the association with low PAPP-A and PTB and PE these pregnancies 
should be assessed comprehensively for other risk factors for PTB and consideration 
given to the commencement of aspirin prior to 16 weeks. The clinical utilisation of 
CRL as an individual prognostic factor (i.e. outside of a model using it as a 
continuous factor) is less clear as standard care in the UK is for a single first trimester 
ultrasound to incorporate dating (using CRL) and NT for aneuploidy risk. Thus, it is 
not possible to determine whether a CRL is larger or smaller than expected. 
 
Independent prognostic factors have a broad array of potential uses in both clinical 
practice and health research (112). For instance, they help to define disease at 
diagnosis; they may be modifiable for interventions to improve outcomes; they aid the 
design and analysis of trials; they are confounders to consider in observational studies 
and unbalanced trials; and they are the building blocks of prognostic models (112). 
Prognostic factor research is therefore important to discover and evaluate such factors. 
We emphasize that our multivariable models were fitted to examine if there is evidence 
of an independent association between the potential prognostic factors of interest and 
the maternal and fetal outcomes after adjustment for known prognostic factors. Our 
objective was to assess the prognostic factors themselves and not on an overall 
prognostic model for individual risk prediction. This is especially important since there 
was no external data to validate such a model (118). Future work could use new 
datasets to develop individual risk prediction models to tailor treatment choices to the 
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individual. Such models should build on the findings of this study, in terms of the 
prognostic factors that were identified as important. 
 
5.6 : Conclusion 
The evidence from this study supports the need for women with pregnancies with a 
low PAPP-A and increased NT being under Consultant led care and the 
recommendation within the international guidelines for increased surveillance for SGA 
in pregnancies with a low PAPP-A and supports this being extended to pregnancies in 
the first trimester with an increased NT. At present until a model is developed that can 
incorporate these factors as continuous variables it would be appropriate to use 
accepted thresholds of <5th centile for PAPP-A and >99th centile for NT. Due to the 
association with low PAPP-A and PTB and PE these pregnancies should be assessed 
comprehensively for other risk factors for PTB and consideration given to the 
commencement of aspirin prior to 16 weeks. The clinical utilization of CRL as an 
individual prognostic factor (i.e. outside of a model using it as a continuous factor) is 
less clear as standard care in the UK is for a single first trimester ultrasound to 
incorporate dating (using CRL) and NT for aneuploidy risk. Thus, it is not possible to 
determine whether a CRL is larger or smaller than expected. 
 
When three first trimester potential prognostic factors are considered in combination 
there remains statistically significant associations between: a) PAPP-A, NT, CRL and 
SGA, b) PAPP-A only with PTB, c) PAPP-A and CRL for PE, d) NT and miscarriage. 
Further work is required to assess the predictive ability of these factors in prediction 
models for adverse pregnancy outcome. 
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Studies have tested the hypothesis that low maternal serum levels of PAPP-A in the first 
trimester are prognostic factors for adverse pregnancy outcomes associated with poor 
placental function (5, 6, 49, 50) . International Guidelines on “The Investigation and 
Management of the Small for Gestational Fetus” have recommended that pregnant 
women with a serum PAPP-A < 0.4MoM (5th centile) in the first trimester receive 




In our  population at Birmingham Women’s Hospital, the  retrospective cohort study 
from 2011-2015 included over 12,000 women and found that there was a significant 
relationship between PAPP-A and adverse pregnancy outcome and after multivariable 
analysis (i.e. adjusting for other factors) there was a lower odds of SGA [adjusted odds 
ratio (OR) 0.87 (95% CI 0.85,0.90)], preterm birth <37 weeks (PTB) [OR 0.92 (95%CI 
0.90,0.96)], pre-eclampsia (PE) [0.91 (95% CI 0.85,0.97)] and stillbirth [OR 0.72 (95% 







This equated in our population at Birmingham Women’s Hospital to the following: 
 
 Background risks: 3 out of 100 women got pre-eclampsia, 6 out of 100 had 
miscarriage (12-24 weeks), 35 out of 10000 had a stillbirth; 67 out of 10000 had a 
perinatal death and 33 out of 10000 had a neonatal death, 8 out of 100 had a 




 Risk if PAPP-A ≤5th centile: 4 out of 100 got pre-eclampsia, 1 out of 100 had a 
miscarriage, 1 out of 100  had  a stillbirth, 15 out of 1000 had  a perinatal death, 6 
out of 1000 a neonatal death, 26 out of 100 a small baby. 
 
 Risk if PAPP-A ≤ 1st centile: 2 out of 100 had PET, 3 out of 100 had a 
miscarriage, 3 out of 100 had a stillbirth, 3 out of 100 had a perinatal loss, 34 out 
of 100 had a small baby and 27 out of 100 had a preterm delivery. 
 
 
6.3 Low PAPP-A SGA pathway 
 
The above findings and national recommendations for PAPP-A MoM to be included in 
the risk assessment for SGA in the RCOG SGA guideline, BWNFT will offer all women 
with a PAPP-A <5
th
 centile serial growth scans. At present women will not be offered a 
PAPP-A estimation as part of routine care as the test has not been approved nor funded 
for clinical use in this manner. Women will therefore only be identified as part of the 




This pathway only applies to women with an isolated low PAPPA i.e. whose combined 
test gives a low risk for trisomy 21, 18 and 13 and in whom the nuchal translucency was 
normal. If women are high risk for chromosomal aberrations or had a NT > 3.5 mm 
they should follow established pathways linking with fetal medicine. If further 
investigations / screening are normal with a low PAPP-A MoM they should have 



























The antenatal screening midwives will identify any women with a low 
PAPP-A Mom using a 0.4 MoM cut off as the 5th centile and 0.2 MoM 
the 1st centile. 
A PAPP-A MoM sticker will be placed on the alert sheet with the 
result documented and a written entry will be made into the 
hospital records. 
Women under midwifery led care and with a PAPP-A MoM less 
than the 1st centile will be sent a letter and leaflet explaining 
the result and a clinic appointment for the specialist growth 
clinic (Dr K Morris Wednesday am) at 20 weeks to coincide with 
the Mid Trimester scan.  
Women booked under consultant led care with a PAPP-A 
MoM result less than the 5th centile but not less than the 
1st centile will be sent a letter and leaflet explaining the 
result and a clinic appointment with their consultant at 20 
weeks to coincide with the Mid Trimester scan. 
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6.3.1 The antenatal screening midwives will identify women with a low 
PAPP-A (Mom using a 0.4 MoM cut off as the 5th centile and 0.2 MoM 
the 1st centile). 
 
1. The screening midwives will obtain the hospital notes pertaining to these 
results. 
 
2. A PAPP-A MoM sticker will be placed on the alert sheet with the result 
documented and a written entry will be made into the hospital records. 
 
3. Women under midwifery led care will be sent a letter (Appendix 2) and a 
leaflet (Appendix 4) explaining the result and a clinic appointment for the 
specialist growth clinic at 20 weeks to coincide with the Mid Trimester 
scan. 
 
4. Women with a PAPP-A MoM less than the 1st centile will also be referred 
to the specialist growth clinic  at 20 weeks to coincide with the Mid 
Trimester scan. (see Appendix 3 – SGA risk assessment and referral to 
specialist growth clinic) 
 
5. Women booked under consultant led care with a PAPP-A MoM result less 
than the 5th centile but not less than the 1st centile will be sent a letter and 
leaflet explaining the result and a clinic appointment with their consultant 




6.3.2 Antenatal clinic appointment plan schedule for women with a 
PAPP-A MoM less than 5th centile (not less than the 1st centile). 
 




20 weeks  
Seen in Consultant ANC, results explained.  
Assess pregnancy for other risk factors for 
pre-eclampsia, SGA or stillbirth (ensure 
completion of 20 week SGA risk assessment 
proforma see Appendix 3). 
Smoking cessation advice given if applicable. 
If isolated PAPP-A then a uterine artery 
Doppler and growth scan should be arranged 
for 24 weeks. 
24 weeks 
Consultant ANC review if there is an abnormal 
uterine artery Doppler [pulsatility index (PI > 2SDs 
or any notching] or evidence of early onset 
growth restriction  (EFW or AC less than 10th 
centile) then the women should be referred to 
the specialist growth clinic and an appointment 
booked within 2 weeks for a personalised plan. 
Serial Growth Scans 
If the Uterine artery Doppler is normal the women 
should have 4 weekly growth scans (28/32/36/40 




20 weeks  
 Seen in Consultant ANC, results explained (see patient information leaflet 
Appendix 4).  
 Assess pregnancy for other risk factors for pre-eclampsia, SGA or stillbirth 
(ensure completion of 20 week SGA risk assessment proforma see Appendix 2). 
 Smoking cessation advice given if applicable. 
 If isolated PAPP-A then a uterine artery Doppler and growth scan should be 
arranged for 24 weeks. 
 
24 weeks 
 Consultant ANC review if there is an abnormal uterine artery Doppler [pulsatility 
index (PI > 2SDs or any notching] or evidence of early onset growth restriction 
(EFW or AC less than 10
th
 centile) then the women should be referred to the 
specialist growth clinic (Dr K Morris Wednesday am) and an appointment booked 
within 2 weeks for a personalised plan. 
 
If the Uterine artery Doppler is normal the patient should have 4 weekly growth scans 








All women with a PAPP-A MoM less than 0.2 MoM (1
st
 centile) will be referred 
directly to the specialist growth clinic for a personalised plan. 
 
6.4 Implementation and Audit 
 
This process will be implemented from the 1
st
 November 2016. 
A database will be kept by the screening midwives and an audit of the process will be 




Above pathway for SGA is one of the many ways to perform surveillance for SGA   in 
women with  low PAPP-A. There is a need for an accurate prediction model before 
performing additional surveillance for other adverse pregnancy outcomes as individual 
predictive values of PAPP-A are poor. 
Once a model is worked out, the additional surveillance for multiple adverse pregnancy 
outcomes like pre eclampsia, stillbirth could include more frequent blood pressure 
measurements, Women may have frequent ‘day assessment ‘appointments to check blood 
pressure, urine dipstick test for protein and fetal surveillance in the form of 
cardiotocogram and checking with fetal movements. Antenatal low dose aspirin from the 
beginning of second trimester could be a potential intervention which needs to be 














This thesis achieves the main objectives set out in chapter 3 - in that it reports:  
1. systematic review and meta-analysis on Association of serum PAPP-A 
levels in first trimester with small-for-gestational-age and other adverse 
pregnancy outcomes. 
2. 2.Retrospective cohort study examining the association of maternal serum 
PAPP-A levels, in first trimester with adverse pregnancy outcomes. 
 
 
In the previous chapters, detailed discussion of the above said topics including 
limitations and strengths has been presented. This chapter focuses on the main findings 
of the work undertaken and discusses its strengths and limitations leading to general 
recommendations for research and practice. 
 
 
7.2 Summary of main findings 
 
7.2.1 Systematic review:  Key points: 
 
 1715 citations found in literature. 
 
 





 Low maternal serum PAPP-A in the first trimester has shown to be 
associated with adverse pregnancy outcome. Though the association is 
statistically significant the predictive values are poor which would mean that 
although women with a low PAPP-A are at increased risk of an adverse outcome, 
the clear majority of these women will have a normal pregnancy outcome and the 
majority of women with an adverse outcome will have a normal PAPP-A. 
 
 
7.2.2 Retrospective cohort study: Key points 
 
 
 Retrospective cohort study conducted at Birmingham woman’s hospital 
NHS foundation trust between 2011 and 2015 with all necessary approvals. 
 
 
 Included 12,592 pregnancies which resulted in 852 (6.8%) PTD, 352 (2.8%) 
PE, 1824 (14.5%) SGA, 73 (0.6%) miscarriages, 37 (0.29%) stillbirths and 38 




 There were statistically significant lower odds of SGA, PTD, PE and stillbirth 
as PAPP-A increases whereas no statistically significant association between 
miscarriage, perinatal or neonatal death was found with PAPP-A. 
 
 
 Low PAPP-A is an independent risk factor for adverse pregnancy outcomes, 
especially SGA. Further work needs to consider how this predictive factor can 
be combined with other risk factors to give accurate prediction for an 




7.3 Strengths of the thesis 
 
7.3.1 Strengths of systematic review 
 
 Comprehensive and robust search strategy. 
 
 
 The review was compliant with recommended techniques for quality 
assessment, (63) (54) performing and interpreting meta-analyses and reporting 
of our findings (56, 71). 
 
 Both prognostic and predictive ability of PAPP-A was demonstrated in the 
review. 
 





7.3.2 Strengths of the cohort study 
 
 Large cohort study looking at multiple pregnancy outcomes providing 
reproducible statistical results. 
 
 
 Our cohort a true representative of the general population due to the health 
service framework in the UK which avoided bias caused by skewed 
demographics. 
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 Confounding factors were taken in to account which are known to affect 
pregnancy outcome and have been adjusted for in our analysis. 
 
 
 We have made an effort to look for lesser researched possible associations such 
as miscarriage and neonatal/perinatal death. 
 
 
7.3.3   Strengths of PAPP-A as a marker: 
 
 PAPP-A is an established marker for aneuploidy and is part of first trimester 
combined screening which is offered to every pregnant lady in the UK and 
possibly worldwide. Therefore, if proved to be associated with adverse 
pregnancy outcomes, PAPP-A will be a very cost effective biomarker guiding 
the clinicians to risk stratify the pregnancies without any extra cost / 
intervention to the patient/healthcare system. We do however appreciate extra 





7.4   Limitations of the thesis 
 
7.4.1   Limitations of systematic review 
 




 There was significant statistical heterogeneity in some analyses which could not 
be accounted for when examining clinical characteristics nor study design and 
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was thus unexplained.




 One limitation in the methodology employed is the need to consider PAPP-A as 
a dichotomous variable i.e. categorization using a threshold. This has limitations 
statistically as it can lead to a loss of power as much of the information is lost, 
classifying very similar factor values as different in opposite sides of the cut-off 
point and the concealment of a potential non-linear relationship between the 




7.4.2   Limitations of Cohort Study 
 
 The data for potential confounding factors was limited to that which is routinely 
collected in our electronic maternity record as this was a retrospective study.
 
 
 Although the databases used were not designed for this study they are populated 
by qualified health professionals and data was obtained from multiple sources to 
allow cross-referencing and checking of outcomes.
 
 
 Our sample was determined by the number of patients available with an 
electronic record and outcome data and thus not determined by a sample size 
calculation. However, the size of the cohort and the number of events for each 






 7.4.3   Limitations of PAPP-A as a marker
 
One of the limitations of PAPP-A as a marker would be that it can be used in 
antenatal period rather than prenatal period. Thus, it really does not help in 
‘preventing’ the adverse event as the under lying pathophysiology leading to 
adverse pregnancy event would have already established. Hence the window of 
golden opportunity to prevent the underlying mechanism leading to the adverse 
pregnancy outcome is lost. However, it does give us a chance to be more 
vigilant in the ‘high risk’ pregnancies where there is scope to change the 
outcome of the pregnancy by being more vigilant and look out for early signs of 
adverse pregnancy outcomes thus identifying and to some extent slowing down 
the process of pathology leading to adverse pregnancy events. Currently it is 
attempted by starting women on low dose aspirin before 16 weeks of pregnancy, 
more frequent blood pressure monitoring and regular growth scans under the 
care of a consultant obstetrician. 
 
 
7.5   Recommendations for practice 
 
 The association could be mentioned during the counselling for screening for 
Down’s syndrome (20) which is done universally in the UK. This needs to be 
done in a balanced way considering the poor predictive value of the test. 
 
 
 The association between PAPP-A and SGA has been identified and there are 
national guidelines suggesting increased surveillance for impaired fetal growth. 
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Our systematic review and the cohort study confirm the association between 
low first trimester maternal serum PAPP-A and SGA. 
 
 
 Systematic review and cohort study explained in this thesis also demonstrates 
the association of first trimester low maternal serum PAPP-A in the first 
trimester has an association with other adverse pregnancy namely pre term birth, 
pre- eclampsia. At present, there are no recommendations/guidelines for 
surveillance for other adverse outcomes e.g. miscarriage, preterm birth, pre-
eclampsia nor for interventions due to the increased risk of stillbirth (e.g. 
induction at term). We do appreciate that the possible extra surveillance comes 
with extra cost and increases maternal anxiety. 
 
 
 Perhaps a national guideline for the management of pregnancies with low 
PAPP-A suggesting the surveillance (e.g. regular growth scans, glucose 
tolerance test) and possible interventions for SGA and other adverse pregnancy 
outcomes (e.g. Aspirin, induction of labor at term) could guide clinicians in 




 It must be recognized that for the individual predictive value are poor and thus 
the majority of adverse outcomes will occur in the group without an abnormally 
low PAPP-A and thus outside any guidelines for increased surveillance or 
intervention. 
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7.6 Recommendations for research 
 
 There is further need to develop robust and accurate prediction models that can 
allow modern day obstetrics to practice truly stratified medicine. 
 
 
 Other possible predictors (e.g. previous obstetric history, CRL: B HCG, uterine 
artery Doppler) could be studied and work could be done on creating a possible 
prediction model to stratify the risk assignment for the pregnancy. 
 
 
 There is scope to look out for prenatal markers along with antenatal markers to 
identify women with high risk pregnancies making it possible to prevent them 
by treating them even before  
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 Publications from our study 
 
 
Morris RK, Bilagi A, Devani P, Kilby MD. Association of serum PAPP-A levels in first 
trimester with small for gestational age and adverse pregnancy outcomes: systematic review and 




Ashwini Bilagi, Danielle L Burke, Richard D Riley, Ian Mills, Mark D Kilby, R. Katie Morris. 
Association of maternal serum PAPP-A levels, nuchal translucency and crown rump length in 
first trimester with adverse pregnancy outcomes: Retrospective cohort study. Accepted on 
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Appendix 1 Search strategy for electronic database identification of Association of 








1. EMBASE; exp PREGNANCY DIABETES MELLITUS 
 
2. EMBASE; (impaired AND blood AND sugar AND in AND pregnancy).ti,ab; 
 
4. EMBASE; (diabetes AND mellitus AND in AND pregnancy).ti,ab; 
 
5. EMBASE; exp PREGNANCY ASSOCIATED PLASMA PROTEIN A/; 
 
6. EMBASE; PAPP-A.ti,ab; 
 
7. EMBASE; (Pregnancy AND associated AND plasma AND protein).ti,ab; 
 
8. EMBASE; 5 OR 6 OR 7; 
 
9. EMBASE; 1 OR 2 OR 3 OR 4; 
 
10. EMBASE; 8 AND 9; 
 
11. EMBASE; (impaired AND glucouse AND tolerance AND in AND pregnancy).ti,ab; 
 
12. EMBASE; (insulin AND resistance AND in AND pregnancy).ti,ab; 
 
13. EMBASE; 8 AND 12; 
 
14. MEDLINE; exp PREGNANCY DIABETES MELLITUS/; 
 
15. MEDLINE; (impaired AND blood AND sugar AND in AND pregnancy).ti,ab; 
 
16. MEDLINE; (gestational AND diabetes AND mellitus).ti,ab; 
 
17. MEDLINE; (diabetes AND mellitus AND in AND pregnancy).ti,ab; 
 
18. MEDLINE; (impaired AND glucose AND tolerance AND in AND pregnancy).ti,ab; 
 
19. MEDLINE; (insulin AND resistance AND in AND pregnancy).ti,ab; 
 
20. MEDLINE; exp DIABETES, GESTATIONAL/ OR exp GLUCOSE TOLERANCE 
TEST/; 
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21. MEDLINE; exp PREGNANCY ASSOCIATED PLASMA PROTEIN A/; 
 
22. MEDLINE; PAPP-A.ti,ab; 
 
23. MEDLINE; (Pregnancy AND associated AND plasma AND protein).ti,ab; 
 
24. MEDLINE; 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20; 
 
25. MEDLINE; 21 OR 22 OR 23; 
 
26. MEDLINE; 24 AND 25; 
 
27. CINAHL; exp PREGNANCY DIABETES MELLITUS/; 
 
28. CINAHL; (impaired AND blood AND sugar AND in AND pregnancy).ti,ab; 
 
29. CINAHL; (gestational AND diabetes AND mellitus).ti,ab; 
 
30. CINAHL; (diabetes AND mellitus AND in AND pregnancy).ti,ab; 
 
31. CINAHL; (impaired AND glucose AND tolerance AND in AND pregnancy).ti,ab; 
 
32. CINAHL; (insulin AND resistance AND in AND pregnancy).ti,ab; 
 
33. CINAHL; exp DIABETES, GESTATIONAL/ OR exp GLUCOSE TOLERANCE 
TEST/; 
34. CINAHL; exp PREGNANCY ASSOCIATED PLASMA PROTEIN A/; 
 
35. CINAHL; PAPP-A.ti,ab; 
 
36. CINAHL; (Pregnancy AND associated AND plasma AND protein).ti,ab; 
 
37. CINAHL; 34 OR 35 OR 36; 
 
38. CINAHL; 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33; 
 
39. CINAHL; 37 AND 38; 
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4. EMBASE; exp PREGNANCY ASSOCIATED PLASMA PROTEIN A/; 
 
5. EMBASE; PAPP-A.ti,ab; 
 
6. EMBASE; (Pregnancy AND associated AND plasma AND protein).ti,ab; 
 
7. EMBASE; 4 OR 5 OR 6; 
 
8. EMBASE; exp PREMATURE LABOR/; 
 
9. EMBASE; exp PREMATURITY/; 
 
10. EMBASE; (pre AND term AND delivery).ti,ab; 
 
11. EMBASE; (pre AND term AND labour).ti,ab; 
 
12. EMBASE; prematurity.ti,ab; 
 
13. EMBASE; (pre AND term AND birth).ti,ab; 
 
14. EMBASE; (premature AND birth).ti,ab; 
 
17. EMBASE; (premature AND delivery).ti,ab; 
 
18. EMBASE; 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 17; 
 
19. EMBASE; 7 AND 18; 
 
20. MEDLINE; PAPP-A.ti,ab; 
 
21. MEDLINE; (Pregnancy AND associated AND plasma AND protein).ti,ab; 
 
22. MEDLINE; 4 OR 20 OR 21; 
 
23. MEDLINE; exp PREMATURE LABOR/; 
 
24. MEDLINE; exp PREMATURITY/; 
 
25. MEDLINE; (pre AND term AND delivery).ti,ab; 
 
26. MEDLINE; (pre AND term AND labour).ti,ab; 
 
27. MEDLINE; prematurity.ti,ab; 
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28. MEDLINE; (pre AND term AND birth).ti,ab; 
 
29. MEDLINE; (premature AND birth).ti,ab; 
 
30. MEDLINE; (premature AND delivery).ti,ab; 
 
31. MEDLINE; 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 15 OR 30; 
 
32. MEDLINE; 22 AND 31; 
 
33. MEDLINE; exp PREGNANCY-ASSOCIATED PLASMA PROTEIN-A/; 
 
35. MEDLINE; 20 OR 21 OR 33; 
 
36. MEDLINE; 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30; 
 
39. MEDLINE; 35 AND 36; 
 
40. CINAHL; PAPP-A.ti,ab; 
 
41. CINAHL; (Pregnancy AND associated AND plasma AND protein).ti,ab; 
 
50. CINAHL; 40 OR 41; 
 
52. CINAHL; exp PREMATURE LABOR/; 
 
53. CINAHL; exp PREMATURITY/; 
 
54. CINAHL; (pre AND term AND delivery).ti,ab; 
 
55. CINAHL; (pre AND term AND labour).ti,ab; 
 
56. CINAHL; prematurity.ti,ab; 
 
57. CINAHL; (pre AND term AND birth).ti,ab; 
 
58. CINAHL; (premature AND birth).ti,ab; 
 
59. CINAHL; (premature AND delivery).ti,ab; 
 
60. CINAHL; 52 OR 53 OR 54 OR 55 OR 56 OR 57 OR 58 OR 59; 
 
61. CINAHL; 50 AND 60; 
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C) PAPP-A & Small for gestation 
 
1. EMBASE; exp PREGNANCY ASSOCIATED PLASMA PROTEIN A/; 
 
2. EMBASE; (pregnancy AND associated AND plasma AND protein AND A).ti,ab; 
 
3. EMBASE; PAPP-A.ti,ab 
 
4. EMBASE; 1 OR 2 OR 3; 
 
5. EMBASE; exp INTRAUTERINE GROWTH RETARDATION/ OR exp FETUS 
GROWTH/ OR exp BIRTH WEIGHT/; 
6. EMBASE; (intrauterine AND growth AND retardation).ti,ab; 
 
7. EMBASE; (intrauterine AND growth AND restriction).ti,ab; 
 
8. EMBASE; (birth AND weight).ti,ab; 
 
9. EMBASE; (fetus AND growth).ti,ab; 
 
10. EMBASE; (fetal AND growth AND anomaly).ti,ab; 
 
11. EMBASE; (prenatal AND growth).ti,ab; 
 
12. EMBASE; (small AND for AND gestational AND age).ti,ab; 
 
13. EMBASE; (small AND for AND gestation AND age).ti,ab; 
 
14. EMBASE; 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13; 
 
15. EMBASE; 4 AND 14; 
 
16. MEDLINE; exp PREGNANCY ASSOCIATED PLASMA PROTEIN A/; 
 
17. MEDLINE; (pregnancy AND associated AND plasma AND protein AND A).ti,ab; 
 
18. MEDLINE; PAPP-A.ti,ab; 
 
19. MEDLINE; 16 OR 17 OR 18; 
 
20. MEDLINE; exp INTRAUTERINE GROWTH RETARDATION/ OR exp FETUS 
GROWTH/ OR exp BIRTH WEIGHT/; 
21. MEDLINE; (intrauterine AND growth AND retardation).ti,ab; 
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22. MEDLINE; (intrauterine AND growth AND restriction).ti,ab; 
 
23. MEDLINE; (birth AND weight).ti,ab; 
 
24. MEDLINE; (fetus AND growth).ti,ab; 
 
25. MEDLINE; (fetal AND growth AND anomaly).ti,ab; 
 
26. MEDLINE; (prenatal AND growth).ti,ab; 
 
27. MEDLINE; (small AND for AND gestational AND age).ti,ab; 
 
28. MEDLINE; (small AND for AND gestation AND age).ti,ab; 
 
29. MEDLINE; 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28; 
 
30. MEDLINE; 19 AND 29; 
 
31. MEDLINE; 19 AND 29; 
 
32. CINAHL; exp PREGNANCY ASSOCIATED PLASMA PROTEIN A/; 
 
33. CINAHL; (pregnancy AND associated AND plasma AND protein AND A).ti,ab; 
 
34. CINAHL; PAPP-A.ti,ab; 
 
35. CINAHL; 32 OR 33 OR 34; 
 
36. CINAHL; exp INTRAUTERINE GROWTH RETARDATION/ OR exp FETUS 
GROWTH/ OR exp BIRTH WEIGHT/; 
37. CINAHL; (intrauterine AND growth AND retardation).ti,ab; 
 
38. CINAHL; (intrauterine AND growth AND restriction).ti,ab; 
 
39. CINAHL; (birth AND weight).ti,ab; 
 
40. CINAHL; (fetus AND growth).ti,ab; 
 
41. CINAHL; (fetal AND growth AND anomaly).ti,ab; 
 
42. CINAHL; (prenatal AND growth).ti,ab; 
 
43. CINAHL; (small AND for AND gestational AND age).ti,ab; 
 
44. CINAHL; (small AND for AND gestation AND age).ti,ab; 
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45. CINAHL; 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44; 
 
46. CINAHL; 35 AND 45; 
 
D) PAPP-A & PET 
 
1. MEDLINE; exp PREGNANCY-ASSOCIATED PLASMA PROTEIN-A/; 
 
2. MEDLINE; PAPP-A.ti,ab; 
 
3. MEDLINE; (Pregnancy AND associated AND plasma AND protein).ti,ab; 
 
4. MEDLINE; 1 OR 2 OR 3; 
 
5. MEDLINE; exp PRE-ECLAMPSIA/; 
 
6. MEDLINE; Pre-eclampsia. Ti,ab; 
 
7. MEDLINE; (toxaemia AND of AND pregnancy).ti,ab; 
 
8. MEDLINE; exp HYPERTENSION, PREGNANCY-INDUCED/; 
 




10. MEDLINE; (pregnancy AND induced AND hypertension).ti,ab; 
 
11. MEDLINE; 5 OR 6 OR 7 OR 8 OR 9 OR 10; 
 
12. MEDLINE; 4 AND 11; 
 
13. MEDLINE; exp PREGNANCY-ASSOCIATED PLASMA PROTEIN-A/; 
 
14. MEDLINE; PAPP-A.ti,ab; 
 
15. MEDLINE; (Pregnancy AND associated AND plasma AND protein).ti,ab; 
 
16. MEDLINE; 13 OR 14 OR 15 
 
17. MEDLINE; exp PRE-ECLAMPSIA/ 
 
18. MEDLINE; Pre eclampsia.ti,ab; 
 
19. MEDLINE; (toxaemia AND of AND pregnancy).ti,ab; 
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20. MEDLINE; exp HYPERTENSION, PREGNANCY-INDUCED/; 
 
21. MEDLINE; exp PREGNANCY COMPLICATIONS, CARDIOVASCULAR/ OR 
exp HYPERTENSION,PREGNANCY-INDUCED/; 
22. MEDLINE; (pregnancy AND induced AND hypertension).ti,ab; 
 
23. MEDLINE; 17 OR 18 OR 19 OR 20 OR 21 OR 22; 
 
24. MEDLINE; 16 AND 23; 
 
25. EMBASE; exp PREGNANCY-ASSOCIATED PLASMA PROTEIN-A/; 
 
26. EMBASE; (Pregnancy AND associated AND plasma AND protein).ti,ab; 
 
27. EMBASE; 25 OR 2 OR 26; 
 
28. EMBASE; (toxaemia AND of AND pregnancy).ti,ab; 
 
29. EMBASE; exp HYPERTENSION, PREGNANCY-INDUCED/; 
 
30. EMBASE; exp PREGNANCY COMPLICATIONS, CARDIOVASCULAR/ OR 
exp HYPERTENSION,PREGNANCY-INDUCED/; 
31. EMBASE; (pregnancy AND induced AND hypertension).ti,ab; 
 
32. EMBASE; exp MATERNAL HYPERTENSION/; 
 
33. EMBASE; (gestational AND hypertension).ti,ab; 
 
34. EMBASE; 28 OR 29 OR 30 OR 31 OR 32 OR 33; 110567 results. 
 
35. EMBASE; 27 AND 34; 
 
13. CINAHL; exp PREGNANCY-ASSOCIATED PLASMA PROTEIN-A/; 
 
14. CINAHL; PAPP-A.ti,ab; 
 
15. CINAHL; (Pregnancy AND associated AND plasma AND protein).ti,ab; 
 
16. CINAHL; 13 OR 14 OR 15; 
 
17. CINAHL; exp PRE-ECLAMPSIA/; 
 
18. CINAHL; (toxaemia AND of AND pregnancy).ti,ab; 
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19. CINAHL; exp HYPERTENSION, PREGNANCY-INDUCED/; 
 




21. CINAHL; (pregnancy AND induced AND hypertension).ti,ab; 
 
22. CINAHL; 17 OR 18 OR 19 OR 20 0R 21; 
 




Appendix 2: Data Collection 
F o r m  
 
Data Collection Sheet 
 
Date:    
 
Reviewer ID:   Paper No:   
 
Year Of Publication:   Language:   
 









Section A: Study Selection 
Population: 
1) Low Risk □ 2) High Risk □ 3) Unselected □ 4) Unreported □ 
Index test: 
Reference number      
Other    
Reference Test / Outcome Measure: 
Fetal growth 
SGA □ 
Pre eclampsia □ 
Gestational diabetes □ 








Yes  □ No □ 
Study Selected: 
Yes  □ No □ Give reason if NO    
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Section and Topic Item  Code 
 
1 2 3 
4 
TITLE, ABSTRACT AND KEYWORDS 
 1 Identify the article as a study 
of diagnostic accuracy 
(recommend MeSH heading “ 
sensitivity and specificity”) 
Yes  □  No  □ Unclear 
□ N/A □ 
INTRODUCTION    
 2 State the research questions or 
aims, such as estimating 
diagnostic accuracy or 
comparing accuracy between 
tests or across participant 
groups 
Yes  □  No  □ Unclear 
□ N/A □ 
METHODS    
Participants 3 Describe the study 
population: the inclusion and 
exclusion criteria and the 
settings and locations where 
the data were collected. 
Yes  □  No  □ Unclear 
□ N/A □ 
 4 Describe participant 
recruitment: was this based 
on presenting symptoms, 
results from previous tests, or 
the fact that the participants 
had received the index tests or 
the reference standard? 
Yes  □  No  □ Unclear 
□ N/A □ 
123  
 
 5 Describe participant 
sampling: was this a 
consecutive series of 
participants defined by 
selection criteria in items 3 and 
4? If not, specify how 




3= unclear 4=N/a 
 6 Describe data collection: was 
data collection planned before 
the index tests and reference 
standard were performed 
(prospective study) or after 
(retrospective study)? 
1= prospective 2= 
retrospective 
3= unclear  4= N/a 
Test Methods 7 Describe the reference 
standards and its rationale. 
Yes  □  No  □ Unclear 
□ N/A □ 
 8 Describe technical 
specifications of material and 
methods involved, including 
how and when measurements 
were taken, or cite references 
for a) index test or b) reference 
test 
Yes  □  No  □ Unclear 
□ N/A □ 
 9 Describe definition of and 
rationale for the units, cut-off 
points, or categories of the 
results of the a) index test and 
b) reference standard. 
Yes  □  No  □ Unclear 
□ N/A □ 
 10 Describe the number, training 
and expertise of the persons 
executing and reading the a) 
index tests and b) reference 
standards. 
Yes  □  No  □ Unclear 
□ N/A □ 
 11 Were the readers of the a) 
index test and b) reference 
standards blind (masked) to the 
results of the other test? 
Yes  □  No  □ Unclear 
□ N/A □ 
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  Describe any other clinical 





12 Describe methods for 
calculating or comparing 
methods of a) diagnostic 
accuracy and the statistical 
methods used to b) quantify 
uncertainty (e.g. 95% CI) 
Yes  □  No  □ Unclear 
□ N/A □ 
 13 Describe methods for 
calculating test reproducibility, 
if done. 
Yes  □  No  □ Unclear 
□ N/A □ 
RESULTS    
Participants 14 Report when study was done, 
including beginning and 
ending dates of recruitment 
Yes  □  No  □ Unclear 
□ N/A □ 
 15 Report clinical and 
demographic characteristics of 
the study population (e.g. age, 
sex, spectrum of presenting 
symptoms, co morbidity, 
current treatments, recruitment 
centres) 
Yes  □  No  □ Unclear 
□ N/A □ 
 16 Report the number of 
participants satisfying the 
criteria for inclusion that did or 
did not undergo the index tests 
and/or the reference standard; 
describe why participants 
failed to receive either test. 
Yes  □  No  □ Unclear 
□ N/A □ 
Test results 17 Report time interval from the 
index tests to the reference 
standard, and any treatment 
administered between. 
Yes  □  No  □ Unclear 
□ N/A □ 
 18 Report distribution of severity 
of disease (define criteria) in 
Yes  □  No  □ Unclear 
□ N/A □ 
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  those with the target condition; 
other diagnoses in participants 
without the target condition. 
 
 19 Report a cross tabulation of the 
results of the index tests 
(including indeterminate and 
missing results) by the results 
of the reference standard; for 
continuous results, the 
distribution of the test results 
by the results of the reference 
standard. 
Yes  □  No  □ Unclear 
□ N/A □ 
 20 Report any adverse events 
form performing the index 
tests or the reference standard. 
Yes  □  No  □ Unclear 
□ N/A □ 
Estimates 21 Report estimates of a) 
diagnostic accuracy and b) 
measures of statistical 
uncertainty (e.g. 95% CI) 
Yes  □  No  □ Unclear 
□ N/A □ 
 22 Report how indeterminate 
results, missing responses and 
outliers of the index tests were 
handled. 
Yes  □  No  □ Unclear 
□ N/A □ 
 23 Report estimates of variability 
of diagnostic accuracy 
between subgroups of 
participants, readers or centres, 
if done. 
Yes  □  No  □ Unclear 
□ N/A □ 
 24 Report estimates of test 
reproducibility, if done. 
Yes  □  No  □ Unclear 
□ N/A □ 
DISCUSSION    
 25 Discuss the clinical 
applicability of the study 
findings. 
Yes  □  No  □ Unclear 
□ N/A □ 
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Domain 1: Patient selection  
A.  Risk of bias  
Describe methods of patient selection:  
 Was a consecutive or random sample of 
patients enrolled? 
Yes/No/Unclear 
 Was a case-control design avoided? Yes/No/Unclear 
 Did the study avoid inappropriate 
exclusions? 
Yes/No/Unclear 




B.  Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test 
and setting): 
Is there concern that the included patients do not 
match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for 
each test) 
A.  Risk of bias  
Describe the index test and how it was conducted and interpreted: 
 Were the index test results interpreted 
without knowledge of the results of the 
reference standard? 
Yes/No/Unclear 
 If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test 
have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
B.  Concerns regarding applicability  
127  
 
Is there concern that the index test, its conduct, or 
interpretation differ from the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
  Domain 3: Reference standard   
A.  Risk of bias  
Describe the reference standard and how it was conducted and interpreted: 
 Is the reference standard likely to correctly 
classify the target condition? 
Yes/No/Unclear 
 Were the reference standard results 
interpreted without knowledge of the results 
of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its 
interpretation have introduced bias? 
RISK: 
LOW/HIGH/UNCLEAR 
B.  Concerns regarding applicability  
Is there concern that the target condition as defined 




Domain 4: Flow and timing  
A.  Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference 
standard or who were excluded from the 2x2 table (refer to flow diagram): 
 
 
Describe the time interval and any interventions between index test(s) and 
reference standard: 
 Was there an appropriate interval between 
index test(s) and reference standard? 
Yes/No/Unclear 
 Did all patients receive a reference standard? Yes/No/Unclear 
 Did patients receive the same reference 
standard? 
Yes/No/Unclear 
 Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: 
LOW/HIGH/UNCLEAR 
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Appendix 6: Characteristics of included studies for systematic review of association and prediction of first trimester maternal 







Population (including risk), 





Time of test 
(weeks) 
Details of index test 
(timing, method, 
threshold) 
Details of reference standard 





Incl :Singleton pregnancy 
Excl: fetal demise, multiple 
Pregnancies, chromosomal or 
structural abnormalities 
Recruitment: Unreported, over 2 
years, Australia 
10273 11-13+6 Kryptor analyser 




PAPP-A ≤ 0.3MoM 
Pregnancy loss (miscarriage, 
stillbirth and neonatal death) 
Low birth weight < 2500 g 
 
Preterm birth <37, 34 or 28 
completed weeks 
Bo-Quing 




2561 10-13 Alpha software 
(Logical Medical 
Systems) for MoM 





 Excl : multiple pregnancies, 
spontaneous abortion, abnormal 
fetal karyotype, fetal structural 
anomalies, intrauterine fetal 
death. 
Recruitment: Retrospective, case 
control 
Taiwan 
    
Carbone 
et al 2012 
Risk: Unselected 
 
Incl: Singleton pregnancy with 
first trimester combined 
screening 
Excl: Multiple pregnancy, 
structural and chromosomal 
anomaly 
Recruitment: Retrospective 
cohort study, July 2003- 
February 2009 
USA 
3329 10-14 Not reported 
 
PAPP-A<5th centile 
for gestational age 
Small for gestational age: birth 








Risk: women undergoing 
Down’s syndrome screening 
Incl: non-smoking women with 
a singleton 
Excl : incomplete or incorrect 
chart record , 
chromosomal/major structural 
abnormalities, abortion at less 
than 24/40, and major maternal 
disease 
Recruitment: April 1999- 
December 2003, retrospective, 
case control 
Taiwan 








PAPP-A <5th centile, 
<0.3 MoM and < 0.5 
MoM 
Small for gestational age: birth 
weight<10th, 5th, or 3rd centile 
Low birth weight <2,500 g 
Conserva 
et al 2010 
Risk: unselected 
 
Incl: All women undergoing 
Downs syndrome screening 
Excl: chromosomal and 
structural anomalies 
Recruitment: retrospective, 
1687 11+2 -13+6 PAPP-A values 
corrected for maternal 
weight and smoking 
PAPP-A ≤ 0.4MoM 
(5th centile) 
Small for gestational age: birth 
weight < 10th centile 
Preterm delivery : <37 weeks 
 
Gestational Hypertension and pre- 






 cohort, January 2007-January 
2008, Italy 
   Placental abruption 
 
Intra-uterine death: Fetal demise 
after 22 weeks 




Incl: patients attending for first 
trimester combined screening 
Excl: History of recurrent 
miscarriage using aspirin, 
heparin or low molecular weight 
heparin, 
fetal anomaly, type 1 diabetes 
mellitus 
Recruitment: prospective, 
cohort, January 2008-March 
2009 
Turkey 
404 11-14 Chemiluminescent 
enzyme immunoassay 
methods (DPC, Los 
Angeles, California, 
USA) 
Corrected for maternal 




PAPP-A < 0.4 MoM 
Low birth weight <2500g 
 
Pregnancy induced hypertension: 
diastolic blood pressure >90mmHg 
after 20 weeks with or without 
proteinuria 
Preterm delivery < 37 weeks 




Incl: All women with first 
trimester screening 
868 11-14 Chemiluminescent 
enzyme immunoassay 
(DPC, Los 
Small for gestational age: birth 











  Angeles,California, 
USA) 
PAPP-A < 0.35 MoM; 




et al 2013 
Risk: Unselected risk 
 
INC: All pregnancies delivered 
at or beyond  24 weeks 
EXC: Multiple pregnancies 
 
Recruitment: retrospective 
observational study consecutive 
enrolment; January 2008- 
October 2011, UK 
12355 10-11+4 Certified by FMF 
correction done for 
FMF factors 







expressed as MoM. 
 
 
PAPP-A <5th (0.39 
MoM), 3rd (0.34 MoM) 
or 1st (0.25 MoM) 
centiles 
Pre-eclampsia as per ISSHP (Early 
requiring delivery < 34 weeks 
Premature delivery: birth before 37 
completed weeks. 
Small for gestational age: birth 
weight <5th percentile for gestational 
age (≠ Mikolajczyk et al) 











Incl : women enrolled in 
FASTER trial, viable singleton 
pregnancy 
Excl: anencephaly or septated 
cystic hygroma, chromosomal or 
structural anomaly, IDDM. 
Recruitment: prospective, cohort 
USA 
33395 10+3 – 13+6 
days 
Enzyme linked two 
site immunosorbent 





PAPP-A ≤ 10th 
(0.52MoM), ≤ 5th 
(0.42MoM) or ≤ 1st 
centile (0.28MoM) 
Spontaneous loss ≤ 24 weeks of 
gestation 
Fetal loss >24 weeks of gestation 
 
Preterm delivery <37 weeks and ≤ 32 
weeks 
Gestational hypertension – blood 
pressure >140/90 mmHg at least two 
occasions at least 6 hours apart with no 
chronic hypertension or significant 
proteinuria 
Pre-eclampsia – gestational 
hypertension in the setting of significant 
proteinuria (300mg/24 hours or 0.1g/l 
on two random samples ≥ 6 hours apart) 
SGA: birth weight<10th and ≤ 5th 
centile* 




Risk: High risk 
 
INC: singleton pregnancy with an 
18- to 24-week ultrasound 
showing evidence of FGR 
198 First trimester Not reported 
Converted to MoM 
Gestational hypertension and pre- 
eclampsia defined according to 






 (EFW<25th percentile according 
to Hadlock) 
 
EXC: multiple pregnancies, 
fetuses with major anomalies, 
infections or aneuploidy, 
pregnancies complicated by 
second trimester premature 
rupture of membranes, patients 
did not delivered at the institution. 
Data collection: unreported. 
Enrolment unreported. 
USA 
  PAPP-A ≤5th centile 
(0.37 MoM) and 
≤10th centile (0.47 
MoM) 
Birth weight percentile (Oken et al., 
2003). 
Intra-uterine death – no definition 
Preterm birth – no definition 
Composite adverse neonatal outcome: 
intrauterine or neonatal death, indicated 







Incl: singleton pregnancy 
Excl: Multiple gestations 
And aneuploidy. 
Recruitment: Retrospective cohort 
study, 2003-2008 
USA 











Small for gestational age: birth weight 
<10th percentile* 
 













Risk Unselected consecutive 
patients 




Consecutive enrolment, cohort 
USA 
2231¥ 11-13+6 Genzyme 
(Cambridge, MA) 
from 2003 to2007 





Hill, NC) from 
2007 to 2008 using 
ELISA. 
Pre-term birth :delivery before 35 
weeks gestation and, secondarily 
as before 32 weeks 
Gome 
z et al 
2014 
Risk :low risk 
 
Incl :Singleton, spontaneous 
conception, maternal age ≤ 38 
years, having first trimester 
combined test 
Excl :Twin pregnancy, maternal 
illness, IVF, fetal malformation, 
aneuploidy 
512 11-13+6 Not reported 
 
 
PAPP-A ≤ 5th 
centile (0.4 MOM) 
Small for gestational age: birth 
weight<10th and 5th centile 
 
 





 Recruitment: Case control, 
retrospective, January 2012-June 
2013 
Spain 









Incl: Participants in California 
Prenatal Screening Program 
EXCL: Missing data, diabetes 
mellitus, chromosomal or neural 
tube defects 




2070 10-13+6 Auto DELFIA; 
Perkin Elmer Life 
Sciences, Waltham, 
MA 




PAPP-A ≤ 5th 
centile 
Early Preterm delivery between 22+0 
and 29+6 weeks subgroups of 
medically indicated and spontaneous. 







Excl: major fetal anomalies, 
TOP, miscarriage of fetal death 
before 24 weeks, pre-eclampsia 
and lost to follow-up 
32850 11-13+6 Not reported Small for gestational age: birth 
weight<5th centile for gestation at 






 Recruitment: Prospective cohort, 
March 2006-September 2009 
UK 
    
Kava 
k et al 
2006 
Risk: low risk 
 
Incl: singleton pregnancy 
attending for first trimester 
screening 
Excl: Women with multiple 
pregnancy, chronic hypertension, 
previously diagnosed diabetes, or 
pregnancy with a prenatal or 
postnatal diagnosis of a 
chromosomal or structural 
abnormality. Women with a 
history of previous 
pre-eclamptic pregnancy, previous 
gestational hypertension, 
gestational diabetes or IUGR 
 
Recruitment: July 2001- July 
2004, enrolment not reported 








PAPP-A various cut 
offs MoM, <5th 
centile (0.4 MoM) 
Small for gestational age :Birth weight 
< 10th centile for gestational age 
 
Gestational hypertension and 
preeclampsia were diagnosed according 













Incl: Singleton pregnancy 
 
Excl :Pregnancies with 
 
abnormal karyotype and major 
abnormalities 
Recruitment: cohort study, 
prospective January 2005- 
December 2007 
Denmark 
9450 8 -13 + 6 Brahm’s Kryptor 
method 
Converted to MoM 
and corrected for 
maternal weight 
PAPP-A threshold 
of  < 0.4 MoM 
Small for gestational age: birth weight 
< 5th centile # 
 
Pre-term delivery <37 weeks 
Krant 




Incl: singleton pregnancy 
Excl: multiple gestation, recent 
vaginal bleeding equivalent to a 
menstrual period, pre-gestational 
diabetes mellitus, pregnancy 
resulting from a donor oocyte 
unknown cytogenetic or 
phenotypic status, previous 
pregnancy affected with Trisomy 
21 or 18, Trisomy  21or 18 this 
8012 10+4-13+6 NTD Laboratories 
in Huntington 
Station, New York 
 
 
PAPP-A <1st,5th and 
>95th and 99th 
centile 
Preterm delivery < 34 weeks. 
 
Small for gestational age: birth weight 





 pregnancy, without delivery 
information, TOP ,fetal loss. 
Recruitment: Prospective cohort 
study. 
USA 











Cohort study, June 2000- 
November 2001 
Australia 






PAPP-A <0.3 MoM 
and <0.5 MoM 
Small for gestational age: birth weight 
<10th centile ,<3rd centiles for 
gestational age New South Wales 
population 






Incl: Chinese women with 
singleton pregnancy 
Excl: miscarriage, IUD, structural 
and chromosomal anomaly 




Converted to MoM 
corrected for maternal 
weight 
Small for gestational age: birth weight 






 Recruitment: Prospective 
Observational study, June 2003- 
November 2004 
China 







Risk: unselected undergoing first 
trimester Downs syndrome 
screening 
Incl:  singleton 
Excl: None reported 
Recruitment: cohort, prospective, 
1/1/2005 – 31/12/2008 
Finland 




(PerkinElmer Life and 
Analytical Sciences, 
Wallac Oy, Turku, 
Finland) 
Converted to MoM 
corrected for maternal 
weight, diabetic status 
and smoking. 




Small for gestational age: birth weight 
< 2 standard deveiations related to 
gestational age, (national sex-specific 
standards) 
Stillbirth defined as fetal death during 
or after the 22nd gestational week or 
birth weight under 500g. 
Mont 
anari 
Risk: Unselected 2134 11-14 Fluorimetric 
immunoassays 
(Kryptor; Brahms, 
Small for gestational age: birth weight 
<10th centile for gestational age Italian 







Incl: Singleton pregnancy 
undergoing first trimester 
combined screening, 11-14 weeks 
Excl: lost follow up, miscarriage, 
TOP 
Recruitment: prospective 
longitudinal study, 2003-2005 
Italy 
  Berlin, Germany), 
 
Converted to MoM 
corrected for maternal 
weight and smoking. 
Fetal growth restriction was defined as: 
1) fetal abdominal circumference was 
<10th centile on at least 2 ultrasound 
examinations, 2-4 weeks apart, 2) a 
Doppler pulsatility index of umbilical 
artery >90th centile; 3) birth weight 
<10th centile for gestational age 






Incl: All singleton pregnancies 
undergoing Downs syndrome 
screening 
Excl :multiple pregnancies 
 
Recruitment: Cohort, 
retrospective, May 1998-July 
1999, UK 






<5th, < 10th  centile and 
< median 
Miscarriage – spontaneous delivery 
<24 completed weeks 
 
Preterm delivery – spontaneous 
delivery <37 weeks and < 34 completed 
weeks 
Gestational diabetes mellitus: Glucose 
tolerance test as per WHO ^ 
Pregnancy induced hypertension: 
diastolic blood pressure 110mmHg or 
more on any one occasion or a diastolic 
blood pressure of 90mmHg or more on 
two consecutive occasions four hours 
apart in women with no pre-existing 





     proteinuric and non proteinuric, 
depending on the presence or absence 
of either > 300 mg of total protein in a 
24-hour urine collection or an 1+ on 
dipstick 
Small for gestational age: Birth weight 
below the 10th, 5th or 3rd centiles for 






Incl: Singleton pregnancy 
delivered at Bharati hospital Pune 
Excl :Multiple pregnancy 
Recruitment :Case control 
India 




Preterm delivery: <37 weeks 
IUGR no definition 
PIH no definition 
Stillbirth no definition 
Pilali 




Incl :Singleton, uterine artery 
Doppler and known outcome 
Excl: 4 with miscarriage, 11 TOP 
Recruitment: Cohort, prospective, 
878 11-14 Kryptor analyser 
(Brahms AG, Berlin, 
Germany), 
Pre-eclampsia: blood pressure systolic 
≥ 140mmHg or diastolic ≥ 90mmHg on 
two recordings 6 hrs apart and with 
proteinuria ≥.300mg in 24 hours or ≥ 
2_ on dipstick 





 consecutive, September 2002 and 
March 2004 
Greece 
  PAPP-A ≤5th (0.41 
MoM) and ≤10th 
centile (0.52 MoM) 
<5th or <10th centile (Alexander et al 
1996)* 
 
Placental abruption : vaginal bleeding 
after mid gestation from a normally 
situated placenta 
Combined adverse outcome: any or one 
of combination of pre-eclampsia, Small 







Incl : Women booking at Life 
Memorial Hospital undergoing 
combined screening 
Excl: records with missing values 
for birth weight, perinatal 
outcome, gestational age at 
delivery was outside 24-43 weeks, 
abnormal or missing karyotype. 
456 10-13+6 Method not reported 
 
Corrected for maternal 
weight 
PAPP-A <5th centile 
(0.4MoM) 
Small for gestational age: birth weight 
< 5thcentile (G.C.S. Smith Scottish 
data 1992-1998). 
Preterm birth <37 completed weeks 
 
Very preterm birth: between 24 and 32 
weeks. gestation 
Moderately preterm delivery between 
33 and 36 wk. gestation 
Spontaneous preterm birth was defined 





 Recruitment: prospective non- 
intervention cohort study 
Romania 
   between 24-36 weeks where labour had 
not been induced. 
Stillbirth was defined as delivery of a 
dead baby at or after 24 weeks 
gestational age and the denominator 
was all births at or after 24 weeks. 
Pre-eclampsia :pregnancy-induced 






Incl: spontaneous conceived 
structurally normal singleton 
pregnancy, living in Kuopio 
catchment area 
Excl: Multiple pregnancies ,major 
structural abnormality, 
miscarriages and induced 
abortions 
Recruitment: Retrospective 
cohort, Finland, January 2005 – 
December 2007 




Converted to MoM and 
corrected for maternal 
weight and diabetes 
 
 
PAPP-A <0.4, < 0.6, < 
0.8, < 1.0 MoM 
Pre-eclampsia: BP>140/90 mmHg with 
proteinuria >0.5g/day 
Pre term delivery: birth before 37 
completed weeks 
Small for gestational age: sex and age 
adjusted birth weight <10th centile 












Incl: Singleton pregnancy 
 
Excl: chromosomal abnormality, 
spontaneous abortions, multiple 
pregnancies, no record. 
Collection :cohort, retrospective, 







PAPP-A adjusted for 
maternal weight, 
smoking status, 
ethnicity and diabetes. 
PAPP-A ≤10th centile 
Gestational hypertension: blood 
pressure>140/90 mmHg 6 hrs apart 
with no chronic hypertension and no 
significant sign of proteinuria. 
Pre-eclampsia :gestational 
hypertensions and proteinuria (0.1 g/l 
i.e. >2+ on dipstick 6 hrs apart or >300 
mg in 24 hrs on 24 hour collection) 
Preterm birth <37 weeks 
 
Small for gestational age : birth weight 










Inclusion :All singleton 
pregnancies 
Excl: missing values for birth 
weight ,missing values for 
perinatal outcome ,records where 
the gestational age at delivery was 
outside 24–43 wk, abnormal or 





8839 8-14 weeks Kryptor immunoassay 
analyzer (Brahms, 
Berlin, Germany; 
formerly supplied by 
CIS-Bio International, 
Burgess Hill, UK). 
Converted to multiples 
of the median (MOMs) 
and corrected for 




PAPP-A ≤ 5th centile 
Small for gestational age: birth weight 
<5th percentile of birth weight for the 
given week of gestation, using 
percentiles derived from 409,541 live 
births in Scotland between 1992–1998 
(G. C. S. Smith, unpublished data). 
Very pre-term delivery :24-32 weeks 
Pre-term delivery <37 weeks 
Stillbirth was defined as delivery of a 
dead baby at or after 24 weeks. 
Pre-eclampsia: Pregnancy- induced 


















Risk: unselected (all women 
























 offered Trisomy 21 screening) 
 
Incl: singleton pregnancies, 11- 
13+6 weeks 
Excl: Structural or chromosomal 
anomalies 
Recruitment: Prospective, 
consecutive, cohort, October 
1999-August 2002 
UK 
4171 11-13+6 (Brahms AG, Berlin, 
Germany), 
PAPP-A ≤ 5th centile 
(0.422MoM) adjusted 
for maternal; weight, 
smoking and ethnicity 
delivery: spontaneous delivery <37/40 
early pre-term <34 weeks 
Pre-eclampsia was defined according to 
ISSHP (i.e. two recordings of diastolic 
blood pressure >90mmHg at least 4h 
apart in previously normotensive 
women and proteinuria ≥300mg or 
more in 24h, or two readings of ++ on 
dipstick analysis of midstream or 
catheter specimen) 
(Brown et al., 2001). 
 
Small for gestational age: birth weight 
< 5th centile for gestational age ( 






Incl: singleton pregnancy 
Excl: multiple pregnancy 
1136 10-14 Kryptor analyser rapid 
random access 
immunoassay (Brahms 
AG, Berlin, Germany), 
Converted to MoM 
Small for gestational age: birth 
weight<10th centile (Slovene reference 





 Recruitment: Retrospective, 
cohort February 1999 – August 
2001, Slovenia 
   
 







Excl: chromosomal or structural 
anomalies. 
Recruitment: July 1998 – June 
2000, Prospective, study design 
unreported 
Israel. 




PAPP-A≤ 0.25 MoM 
and ≤ 0.50 MoM 
Spontaneous preterm delivery: delivery 
prior to 37 completed weeks 
Fetal growth restriction: birth weight 
<5th percentile for gestational age 
 
Pregnancy induced hypertension: 
Diastolic blood pressure of 110 mmHg 
on one occasion or greater than 90 
mmHg on at least two consecutive 
occasions, 4 h apart with no history of 
pre-existing hypertension or renal 
disease; further subdivided into 
proteinuric (presence of >300 mg total 
protein on a 24 h urine collection or >1 
+ albumin on a single dip-stick 
examination) and non-proteinuric. 
Intra-uterine fetal demise was defined 
as fetal death before delivery and 
after 23 completed weeks of 
gestation. 
Spontaneous miscarriage was defined 





     weeks of gestation. 
 
Placental abruption: Grade 2 or 3 
placental abruption. 
Oligohydramnios: amniotic fluid index 
<5 cm. 
 





Footnote: Incl: inclusion; excl: exclusion; PAPP-A pregnancy associated plasma protein A; MoM multiples of the median; g grams; mmHg 
millimetres of mercury; FMF Fetal Medicine Foundation; ISSHP International Society for Study of Hypertension in Pregnancy; IDDM 
insulin dependent diabetes mellitus; FGR fetal growth restriction; EFW estimated fetal weight; NICU neonatal intensive care unit; 
termination of pregnancy; IUGR intrauterine growth restriction; IUD intrauterine death; WHO World Health Organisation; PIH pregnancy 
induced hypertension; BP blood pressure; UK United Kingdom; USA United States of America. 
* Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 
1996;87:163-8. 
$ Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet 
Gynecol 183 (2000) 
 
# Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal 
weights. Acta Paediatr 1996; 85: 843–848. 
 





¥ Yudkin PL, Aboualfa M, Eyre JA, Redman CW, Wilkinson AR. New birthweight and head circumference centiles for gestational ages 24 
to 42 weeks. Early Hum Dev 1987; 15: 45-52. 
 
† Verdenik I. 2000. Slovenski referenˇcni standardi za teˇzo, dolˇzino in obseg glavice ob rojstvu za doloˇceno gestacijsko starost 
populacije, rojene v letih 1987–96. Zdrav Vestn 69: 153–156. 
 
≠ Mikolajczyk RT, Zhang J, Betran AP, et al. A global reference for fetal weight and birthweight percentiles. Lancet 2011;37:1855–61. 
 
∞ Davey DA, MacGillivray I. 1988. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 
158: 892–898. 
 
¥ Note the two papers by Goetzinger are separate publications with different outcomes but include the same cohort of women. 
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Appendix 7: Forest plots for Pregnancy associated plasma protein A and association 

















Appendix 8: National Research Ethics Services Declaration of a 





DECLARATION OF THE END OF A STUDY 
 
(For all studies except clinical trials of investigational medicinal products) 
 
 
To be completed in typescript by the Chief Investigator and submitted to the Research 
Ethics Committee that gave a favourable opinion of the research (“the main REC”) within 
90 days of the conclusion of the study or within 15 days of early termination. For questions 
with Yes/No options please indicate answer in bold type. 
 
 




Name: Professor Mark Kilby 
Address:  
 
University of Birmingham 
Birmingham 
B15 2TT 
Telephone: 0121 627 2778 
Email: m.d.kilby@bham.ac.uk 
Fax: 0121 623 6875 
 
 





Full title of study: Association of serum PAPP-A levels in first 
trimester with small for gestational age and other 
adverse Pregnancy outcomes: systematic review 
and retrospective cohort study. 
Research sponsor: Birmingham Women’s Hospital 
Name of main REC: NRES Committee North West – Preston 
Main REC reference number: 14/NW/1394 
 
 




Date study commenced: 1/11/14 
Date study ended: 1/3/2016 
Did this study terminate prematurely? No 
 
If yes please complete sections 4, 5 & 6, if no 
please go direct to section 7. 
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Is this a temporary halt to the study? Yes / No 
If yes, what is the justification for 
temporarily halting the study? When 
do you expect the study to re-start? 
e.g. Safety, difficulties recruiting participants, trial 
has not commenced, other reasons. 
 
 




Are there any potential implications 
for research participants as a result of 
terminating/halting the study 
prematurely? Please describe the 
steps taken to address them. 
 












Is a summary of the final report on 



















Print name: Professor Mark Kilby 
Date of submission: 3/3/2016 
157 
Appendix 9: National Research Ethics Services letter of final 
approval for the retrospective cohort study for association of first 
trimeser maternal serum PAPP-A levels with small for gestation 
age and other adverse pregnancy outcomes 







Appendix 10 :BWNFT research and developmen letter of approval for the 
retrospective cohort study forstudy of association of serum PAPP -A levels in first 
trimester with small for gestational age and other adverse Pregnancy outcomes 











Appendix 11: Nuchal translucency and adverse pregnancy outcomes 
 
 
Table 14a: Nuchal translucency (mm): results from unadjusted logistic regression 
(singleton pregnancies) 
 
Outcome Odds Ratio 95% Confidence Interval OR p-value 
SGA 0.811 0.721 to 0.912 <0.0001 
Pre-term labour 1.149 0.998 to 1.322 0.053 
Pre-eclampsia 0.897 0.703 to 1.143 0.378 
Miscarriage 1.942 1.538 to 2.452 <0.0001 
Stillbirth 0.765 0.350 to 1.675 0.503 
Perinatal death 0.696 0.394 to 1.231 0.213 
Neonatal death 0.568 0.250 to 1.288 0.176 
 
 
For a one unit increase in nuchal translucency (NT), the estimated OR of 0.81 for IUGR suggests 
that there are 19% lower odds of SGA, with a 95% CI of between 8.8% and 17.9% lower odds 
(p<0.0001). 
There is some evidence of an association between NT and pre-term labour with an odds ratio 
estimate of 1.15 (95% CI: 0.99 to 1.32; p=0.053), which suggests that the odds of pre-term 
labour increase as NT increases. Similarly, there is highly statistically significant evidence that 
the odds of miscarriage are higher as NT increases with an odds ratio estimate of 1.94 (95% CI: 
1.54 to 2.45; p<0.0001). There is no evidence of a statistically significant association between 
NT and pre-eclampsia, stillbirth, perinatal death or neonatal death. 
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Table 14b: Nuchal translucency: Results from adjusted logistic regression for SGA 










Nuchal translucency (mm) 0.794 0.704 to 0.894 <0.0001 
Mother’s age (years) 1.014 1.004 to 1.025 0.006 
BMI 1.014 1.002 to 1.025 0.018 
Parity 
0 1.141 1.022 to 1.275 0.019 
>4 1.034 0.640 to 1.770 0.893 
Ethnicity 
South-Asian 0.896 0.726 to 1.106 0.306 
Oriental 0.816 0.567 to 1.174 0.274 
Other Mixed 0.778 0.560 to 1.011 0.060 
White 0.786 0.650 to 0.951 0.013 
Deprivation 
score categories 
2 1.097 0.774 to 1.554 0.604 
3 1.009 0.741 to 1.373 0.956 
4 1.020 0.750 to 1.385 0.902 
5 1.173 0.868 to 1.584 0.299 
Smoking status 
Yes 2.694 2.347 to 3.092 <0.0001 
Stopped 1.198 0.901 to 1.593 0.213 
IVF 0.682 0.446 to 1.042 0.077 




In this adjusted analysis, there is evidence of lower odds of SGA as NT increases with 
an odds ratio estimate of 0.80. The estimate is statistically significant with a 95% 
confidence interval of 0.71 to 0.90, suggesting between 10% and 29% lower odds of 
SGA (p=0.001) for a one unit increase in NT, having adjusted for mother’s age, BMI, 
parity, ethnicity, deprivation score, smoking status, IVF status, and gestational diabetes. 
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Table 14c: Nuchal translucency: Results from adjusted logistic regression for 
preterm birth (singleton pregnancies, M=35 imputed datasets) 
 







Nuchal translucency (mm) 1.085 0.926 to 1.272 0.313 
Mother’s age (years) 1.007 0.993 to 1.022 0.291 
BMI 1.002 0.986 to 1.018 0.764 
Parity 
0 1.012 0.859 to 1.193 0.886 
>4 0.989 0.492 to 1.985 0.974 
Ethnicity 
South-Asian 0.755 0.565 to 1.009 0.058 
Oriental 0.439 0.239 to 0.806 0.008 
Other Mixed 0.719 0.499 to 1.033 0.075 
White 0.670 0.540 to 0.907 0.007 
Deprivation 
score categories 
2 0.855 0.520 to 1.407 0.538 
3 0.861 0.562 to 1.320 0.493 
4 0.914 0.599 to 1.394 0.675 
5 1.053 0.697 to 1.592 0.807 
Smoking status 
Yes 1.687 1.371 to 2.076 <0.0001 
Stopped 0.921 0.587 to 1.445 0.721 
IVF 1.091 0.647 to 1.840 0.744 




In this adjusted analysis, there is no evidence of an association between NT and 
preterm birth with an odds ratio estimate of 1.09 (95% CI: 0.93 to 1.28; p=0.294) 
After adjusting for the other predictors.
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Table 14d: Nuchal translucency: Results from adjusted logistic regression for pre- 








Nuchal translucency (mm) 0.870 0.674 to 1.123 0.287 
Mother’s age (years) 1.014 0.992 to 1.035 0.218 
BMI 1.056 1.034 to 1.078 <0.0001 
Parity 
0 2.575 2.012 to 3.293 <0.0001 
>4 1.000 - - 
Ethnicity 
South-Asian 0.641 0.429 to 0.958 0.030 
Oriental 0.319 0.124 to 0.823 0.018 
Other Mixed 0.486 0.279 to 0.849 0.011 
White 0.598 0.420 to 0.853 0.004 
Deprivation 
score categories 
2 0.688 0.365 to 1.297 0.247 
3 0.703 0.412 to 1.199 0.196 
4 0.616 0.360 to 1.053 0.077 
5 0.811 0.483 to 1.362 0.428 
Smoking status 
Yes 0.601 0.389 to 0.928 0.022 
Stopped 0.969 0.536 to 1.753 0.918 
IVF 1.697 0.974 to 2.956 0.062 




In this adjusted analysis, there is no evidence of an association between NT and pre- 
eclampsia with an odds ratio estimate of 0.88 (95% CI: 0.68 to 1.13; p=0.314) after 











Table 14e4: Nuchal translucency: Results from adjusted logistic regression for 
miscarriage (singleton pregnancies, M=35 imputed datasets) 
 







Nuchal translucency (mm) 1.748 1.123 to 2.721 0.013 
Mother’s age (years) 0.964 0.901 to 1.031 0.285 
BMI 1.040 0.984 to 1.104 0.157 
Parity 
0 0.546 0.257 to 1.163 0.117 
>4 1.000 - - 
Ethnicity 
South-Asian 1.362 0.362 to 5.121 0.647 
Oriental 1.000 - - 
Other Mixed 1.529 0.337 to 6.942 0.582 
White 0.846 0.243 to 2.942 0.792 
Deprivation 
score categories 
2 1.000 - - 
3 0.869 0.100 to 7.525 0.899 
4 1.765 0.225 to 13.839 0.589 
5 1.188 0.151 to 9.313 0.870 
Smoking status 
Yes 0.743 0.249 to 2.221 0.595 
Stopped 0.785 0.105 to 5.864 0.813 
IVF 2.188 0.281 to 17.028 0.454 







In this adjusted analysis, there is evidence of higher odds of miscarriage as NT increases 
with an odds ratio estimate of 1.75. The estimate is statistically significant with a 95% 
confidence interval of 1.12 to 2.72, suggesting between 12% and 272% higher odds of 
miscarriage (p=0.001) for a one unit increase in NT, having adjusted for mother’s age, 
BMI, parity, ethnicity, deprivation score, smoking status, IVF status, and gestational 
diabetes. 
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Table 14f: Nuchal translucency: Results from adjusted logistic regression for 
stillbirth (singleton pregnancies, M=35 imputed datasets) 
 
 







Nuchal translucency (mm) 0.694 0.249 to 1.935 0.485 
Mother’s age (years) 0.980 0.9032to 1.066 0.637 
BMI 1.033 0.959 to 1.113 0.394 
Parity 
0 1.832 0.761 to 4.408 0.177 
>4 1.000 - - 
Ethnicity 
South-Asian 2.783 0.337 to 22.954 0.342 
Oriental 1.000 - - 
Other Mixed 1.122 0.069 to 18.129 0.936 
White 1.820 0.233 to 14.198 0.568 
Deprivation 
score categories 
2 0.546 0.068 to 4.396 0.569 
3 1.079 0.375 to 3.106 0.888 
4 0.976 0.347 to 2.744 0.963 
5 1.000 -  
Smoking status 
Yes 1.000 - - 
Stopped 1.051 0.139 to 7.968 0.961 
IVF 1.000 - - 
Gestational diabetes 1.000 - - 
N=9,753 
In this adjusted analysis, there is no evidence of an association between NT and 
stillbirth with an odds ratio estimate of 0.68 (95% CI: 0.24 to 1.90; p=0.460) after 
adjusting for the other predictors. 
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Table 14g: Nuchal translucency: Results from adjusted logistic regression for 
perinatal death (singleton pregnancies, M=35 imputed datasets) 
 
Perinatal death (death between 







Nuchal translucency (mm) 0.888 0.431 to 1.828 0.746 
Mother’s age (years) 0.960 0.903 to 1.022 0.199 
BMI 1.075 1.025 to 1.128 0.003 
Parity 
0 2.173 1.128 to 4.187 0.020 
>4 1.000 - - 
Ethnicity 
South-Asian 0.657 0.260 to 1.657 0.373 
Oriental 0.428 0.052 to 3.547 0.432 
Other Mixed 0.384 0.100 to 1.478 0.164 
White 0.261 0.109 to 0.624 0.003 
Deprivation 
score categories 
2 2.255 0.804 to 6.319 0.122 
3 0.961 0.392 to 2.356 0.931 
4 1.176 0.553 to 2.500 0.674 
5 1.000 - - 
Smoking status 
Yes 0.879 0.298 to 2.598 0.816 
Stopped 1.439 0.339 to 6.117 0.622 
IVF 1.000 - - 
Gestational diabetes 1.000 - - 
N=10,898 
 
In this adjusted analysis, there is no evidence of an association between NT and perinatal death 












Table 14h: Nuchal translucency: Results from adjusted logistic regression for 
neonatal death (singleton pregnancies, M=35 imputed datasets) 
 
Neonatal death (death between 






Nuchal translucency (mm) 1.069 0.391 to 2.926 0.896 
Mother’s age (years) 0.949 0.866 to 1.040 0.262 
BMI 1.117 1.051 to 1.188 <0.0001 
Parity 
0 2.387 0.921 to 6.185 0.073 
>4 1.000 - - 
Ethnicity 
South-Asian 0.437 0.136 to 1.410 0.166 
Oriental 0.617 0.069 to 5.596 0.665 
Other Mixed 0.257 0.051 to 1.308 0.102 
White 0.064 0.018 to 0.221 0.000 
Deprivation 
score categories 
2 5.690 1.618 to 20.015 0.007 
3 0.385 0.048 to 3.080 0.368 
4 1.247 0.422 to 3.684 0.689 
5 1.000 - - 
Smoking status 
Yes 2.964 0.881 to 9.975 0.079 
Stopped 2.204 0.277 to 17.522 0.455 
IVF 1.000 - - 




In this adjusted analysis, there is no evidence of an association between NT and 
neonatal death with an odds ratio estimate of 1.064 (95% CI: 0.38 to 2.99; p=0.907) 
after adjusting for the other predictors. 
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Appendix 12 Crown rump length and adverse pregnancy outcomes 
 
 
Table 55a: Crown rump length (mm): results from unadjusted logistic regression 
(singleton pregnancies) 
 
Outcome Odds Ratio 95% Confidence Interval OR p-value 
SGA 0.994 0.988 to 1.000 0.065 
Pre-term labour 0.999 0.990 to 1.007 0.730 
Pre-eclampsia 1.010 0.997 to 1.023 0.123 
Miscarriage 1.021 0.993 to 1.049 0.147 
Stillbirth 0.971 0.932 to 1.011 0.150 
Perinatal death 0.980 0.952 to 1.008 0.160 
Neonatal death 0.984 0.946 to 1.024 0.432 
 
 
There is some evidence of lower odds of SGA crown rump length (CRL) increases, but 
this is not statistically significant at the 5% significance level (0.065). There is no 
statistical evidence of an association between CRL and any of the other six outcomes. 
For interpretation, for example, for a one unit increase in CRL (mm?), the estimated OR 
of 0.984 for neonatal death suggests that the odds of SGA are lower by 1.6%, with a 
95% CI of between 5.4% lower and 2.4% higher (p=0.432) odds of SGA. 
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Table 15b: Crown rump length: Results from adjusted logistic regression for SGA 










Crown rump length (mm) 0.994 0.988 to 1.000 0.057 
Mother’s age (years) 1.014 1.003 to 1.024 0.006 
BMI 1.013 1.001 to 1.025 0.025 
Parity 
0 1.144 1.025 to 1.278 0.016 
>4 1.024 0.634 to 1.655 0.922 
Ethnicity 
South-Asian 0.890 0.721 to 1.100 0.280 
Oriental 0.791 0.550 to 1.138 0.208 
Other Mixed 0.776 0.598 to 1.007 0.056 
White 0.777 0.642 to 0.940 0.009 
Deprivation 
score categories 
2 1.096 0.773 to 1.552 0.608 
3 1.015 0.746 to 1.381 0.925 
4 1.024 0.754 to 1.391 0.879 
5 1.176 0.870 to 1.579 0.235 
Smoking status 
Yes 2.680 2.335 to 3.075 <0.0001 
Stopped 1.188 0.894 to 1.579 0.235 
IVF 0.680 0.445 to 1.040 0.075 
Gestational diabetes 1.001 0.811 to 1.238 0.986 
N=12,299 
 
In this adjusted analysis, there is evidence of lower odds of SGA as CRL increases with 
an odds ratio estimate of 0.99. The estimate is just statistically significant with a 95% 
confidence interval of 0.99 to 1.00, suggesting between 0% and 1% lower odds of SGA 
(p=0.051) for a one unit increase in CRL, having adjusted for mother’s age, BMI, 
parity, ethnicity, deprivation score, smoking status, IVF status, and gestational diabetes. 
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Table15c: Crown rump length: Results from adjusted logistic regression for 
preterm birth (singleton pregnancies, M=35 imputed datasets) 
 







Crown rump length (mm) 0.998 0.989 to 1.007 0.624 
Mother’s age (years) 1.008 0.994 to 1.023 0.259 
BMI 1.000 0.987 to 1.019 0.731 
Parity 
0 1.011 0.858 to 1.192 0.894 
>4 0.991 0.493 to 1.989 0.979 
Ethnicity 
South-Asian 0.754 0.564 to 1.008 0.057 
Oriental 0.444 0.242 to 0.814 0.009 
Other Mixed 0.719 0.500 to 1.035 0.076 
White 0.699 0.539 to 0.907 0.007 
Deprivation 
score categories 
2 0.855 0.520 to 1.406 0.536 
3 0.860 0.562 to 1.318 0.490 
4 0.914 0.599 to 1.394 0.675 
5 1.055 0.698 to 1.595 0.798 
Smoking status 
Yes 1.689 1.373 to 2.078 <0.0001 
Stopped 0.926 0.590 to 1.451 0.736 
IVF 1.100 0.652 to 1.857 0.720 





In this adjusted analysis, there is no evidence of an association between CRL and 




Table 15d: Crown rump length: Results from adjusted logistic regression for pre- 








Crown rump length (mm) 1.006 0.993 to 1.020 0.325 
Mother’s age (years) 1.012 0.991 to 1.034 0.257 
BMI 1.055 1.033 to 1.078 <0.0001 
Parity 
0 2.573 2.012 to 3.292 <0.0001 
>4 1.000 - - 
Ethnicity 
South-Asian 0.647 0.433 to 0.967 0.034 
Oriental 0.317 0.123 to 0.817 0.017 
Other Mixed 0.489 0.280 to 0.853 0.012 
White 0.603 0.426 to 0.859 0.005 
Deprivation 
score categories 
2 0.692 0.368 to 1.304 0.255 
3 0.706 0.415 to 1.204 0.202 
4 0.618 0.361 to 1.057 0.079 
5 0.809 0.482 to 1.359 0.424 
Smoking status 
Yes 0.601 0.390 to 0.928 0.022 
Stopped 0.959 0.530 to 1.734 0.890 
IVF 1.660 0.953 to 2.892 0.073 




In this adjusted analysis, there is no evidence of an association between CRL and pre 
eclampsia with an odds ratio estimate of 1.01 (95% CI: 0.99 to 1.02; p=0.357) after 
adjusting for the other predictors .
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Table 15e: Crown rump length: Results from adjusted logistic regression for 
miscarriage (singleton pregnancies, M=35 imputed datasets) 
 







Crown rump length (mm) 1.031 0.991 to 1.073 0.130 
Mother’s age (years) 0.963 0.901 to 1.031 0.279 
BMI 1.044 0.986 to 1.106 0.141 
Parity 
0 0.540 0.255 to 1.147 0.109 
>4 1.000 - - 
Ethnicity 
South-Asian 1.427 0.379 to 5.367 0.599 
Oriental 1.000 - - 
Other Mixed 1.596 0.352 to 7.237 0.544 
White 0.914 0.263 to 3.176 0.887 
Deprivation 
score categories 
2 1.000 - - 
3 0.840 0.097 to 7.265 0.874 
4 1.717 0.219 to 13.447 0.607 
5 1.185 0.151 to 9.275 0.872 
Smoking status 
Yes 0.755 0.253 to 2.254 0.615 
Stopped 0.804 0.108 to 5.991 0.831 
IVF 2.055 0.265 to 15.953 0.491 





In this adjusted analysis, there is no evidence of an association between CRL and 
miscarriage with an odds ratio estimate of 1.03 (95% CI: 0.99 to 1.07; p=0.130) after 










Table 15f: Crown rump length: Results from adjusted logistic regression for 
stillbirth (M=35 imputed datasets) 







Crown rump length (mm) 0.940 0.890 to 0.993 0.027 
Mother’s age (years) 0.987 0.908 to 1.074 0.769 
BMI 1.033 0.958 to 1.113 0.401 
Parity 
0 1.867 0.775 to 4.499 0.164 
>4 1.000 - - 
Ethnicity 
South-Asian 2.542 0.308 to 21.009 0.387 
Oriental 1.000 - - 
Other Mixed 1.078 0.067 to 17.411 0.958 
White 1.643 0.210 to 12.857 0.636 
Deprivation 
score categories 
2 0.513 0.064 to 4.136 0.531 
3 1.076 0.374 to 3.092 0.892 
4 0.967 0.344 to 2.718 0.949 
5 1.000 - - 
Smoking status 
Yes 1.000 - - 
Stopped 1.071 0.141 to 8.134 0.946 
IVF 1.000 - - 




In this adjusted analysis, there is evidence of lower odds of stillbirth as CRL increases 
with an odds ratio estimate of 0.94. The estimate is just statistically significant with a 95% 
confidence interval of 0.89 to 0.99, suggesting between 1% and 11% lower odds of 
stillbirth (p=0.027) for a one unit increase in CRL, having adjusted for mother’s age, BMI, 













Table 15g: Crown rump length: Results from adjusted logistic regression for 
perinatal death (singleton pregnancies, M=35 imputed datasets) 
 
Perinatal death (death between 







Crown rump length (mm) 0.970 0.934 to 1.007 0.110 
Mother’s age (years) 0.964 0.906 to 1.026 0.245 
BMI 1.075 1.025 to 1.128 0.003 
Parity 
0 2.190 1.136 to 4.223 0.019 
>4 1.000 - - 
Ethnicity 
South-Asian 0.631 0.249 to 1.560 0.330 
Oriental 0.408 0.049 to 3.376 0.405 
Other Mixed 0.379 0.098 to 1.459 0.158 
White 0.250 0.105 to 0.598 0.001 
Deprivation 
score categories 
2 2.192 0.781 to 6.147 0.136 
3 0.953 0.389 to 2.333 0.916 
4 1.161 0.546 to 2.466 0.698 
5 1.000 - - 
Smoking status 
Yes 0.870 0.295 to 2.570 0.802 
Stopped 1.454 0.342 to 6.182 0.612 
IVF 1.000 - - 




In this adjusted analysis, there is no evidence of an association between CRL and 
perinatal death with an odds ratio estimate of 0.97 (95% CI: 0.93 to 1.01; p=0.108) after 
adjusting for the other predictors. 
178  
Table 15h: Crown rump length: Results from adjusted logistic regression for 
neonatal death (singleton pregnancies, M=35 imputed datasets) 
 
Neonatal death (death between 






Crown rump length (mm) 0.997 0.947 to 1.050 0.919 
Mother’s age (years) 0.949 0.866 to 1.040 0.268 
BMI 1.118 1.051 to 1.188 <0.0001 
Parity 
0 2.389 0.921 to 6.192 0.073 
>4 1.000 - - 
Ethnicity 
South-Asian 0.436 0.135 to 1.406 0.165 
Oriental 0.621 0.070 to 5.515 0.669 
Other Mixed 0.258 0.051 to 1.308 0.102 
White 0.064 0.019 to 0.221 <0.0001 
Deprivation 
score categories 
2 5.676 1.612 to 19.983 0.007 
3 0.383 0.048 to 3.065 0.366 
4 1.241 0.420 to 3.667 0.697 
5 1.000 - - 
Smoking status 
Yes 2.952 0.876 to 9.945 0.081 
Stopped 2.213 0.278 to 17.590 0.453 
IVF 1.000 - - 





In this adjusted analysis, there is no evidence of an association between CRL and 
neonatal death with an odds ratio estimate of 0.997 (95% CI: 0.95 to 1.05; p=0.916) 
after adjusting for the other predictors. 
 
Appendix 13: 
Table 3: Adjusted odds ratio estimates for the association between each adverse outcome and PAPP-A, nuchal translucency and crown rump length. 
 
Outcome 
PAPP-A (U/L) OR (95% CI), p- 
value 
 
NT (mm) OR (95% CI), p-value 
CRL (mm) OR (95% CI), p- 
value 
SGA (<10th customised centile) 0.87 (0.85 to 0.90), <0.0001 0.80 (0.71 to 0.90), <0.0001 0.99 (0.99 to 1.00), 0.051 
Preterm birth (<37 weeks) 0.92 (0.90 to 0.96), 0.001 1.09 (0.93 to 1.28), 0.294 1.00 (0.99 to 1.01), 0.614 
Pre-eclampsia toxaemia 0.91 (0.85 to 0.97), 0.004 0.88 (0.68 to 1.13), 0.314 1.01 (0.99 to 1.02), 0.357 
Miscarriage (death <24 weeks 
gestation) 
 
1.01 (0.84 to 1.21), 0.912 
 
1.75 (1.12 to 2.72), 0.013 
 
1.03 (0.99 to 1.07), 0.130 
Stillbirth (death >24 weeks gestation) 0.72 (0.53 to 0.99), 0.044 0.68 (0.24 to 1.90), 0.460 0.94 (0.89 to 0.99), 0.027 
Perinatal death (death between 24 
weeks gestation and 7 days after birth) 
 
0.88 (0.73 to 1.05), 0.164 
 
0.88 (0.42 to 1.82), 0.730 
 
0.97 (0.93 to 1.01), 0.108 
Neonatal death (death between birth 
and 28 days) 
 
1.03 (0.83 to 1.27), 0.786 
 
1.06 (0.38 to 2.99), 0.907 
 
1.00 (0.95 to 1.05), 0.916 
OR odds ratio; CI confidence interval; NT nuchal translucency; CRL crown rump length; SGA small for gestational age; all odds ratio estimates for 
























Following your recent blood tests we have noted that one of your hormone levels is a 
little lower than we would expect and for that reason we would like to invite you to attend 
for a consultant appointment at the time of your 20 week scan to discuss this further. A 
low level of hormone is sometimes associated with smaller babies, so we take the 
precaution of offering you extra surveillance during the pregnancy to monitor this; there 
is no cause for alarm. 
 
Please do not hesitate to contact us if you would like further information before your 


























Appendix 16:  Patient information leaflet for low PAPP-A results. 
 




Risk assessment at booking. High/Low
20 weeks assessment




Antenatal admission - reassess risk High/Low
Risk assessment and algorithm:
 
Algorithm of care
Please complete for all women at booking, 20 weeks and third trimester.
High Risk Care
Serial assessment of referral 
weight and umbilical Doppler from
26-28 weeks until birth;  Scheduled
scans 28/32/36/40 weeks.
EFWs plotted on customised chart.
Low Risk 
□ No known risk factors 
High Risk: one or more of the following:
Maternal Risk Factors
□ Maternal age ≥40 years at term
□ Smoker (ongoing at booking)
□ Drug misuse
Previous Pregnancy History













□ PAPP-A <0.4 MoM (5th centile)
□ Fetal echogenic bowel
Late Pregnancy
□ Severe pregnancy induced hypertension 
or pre-eclampsia (PIH and proteinuria)
□ Unexplained antepartum 
haemorrhage
Direct referral for 
assessment within 72 hours 
for estimated fetal weight 
(EFW), liquor volume and 
umbilical artery Doppler 
Low Risk Care
Serial assessment (2-3 weekly) of fundal 
height (FH) from 26-28 weeks until birth 
FH measurements plotted on customised 
chart
Abnormal growth: 
- cust EFW <10th centile 
and/or
- Serial measurements not       
following curve and/or 
- abnormal umbilical artery 
Doppler
Suspected abnormal growth: 
FH <10th centile or not 















Information for parents:  
Low Pregnancy associated plasma protein (PAPP-A) 
You have been given this leaflet as you have a low PAPP-A on the combined screening test. 
 
What is PAPP-A?  
Pregnancy associated plasma protein A (PAPP-A) is a hormone that is produced by the placenta 
in pregnancy. It is one of two hormones that are measured during the 12 week combined 
screening test.  
Low levels of PAPP-A can be associated with Down’s  Syndrome (an extra chromosome 21), 
Edward’s (extra chromosome 18) and Patau’s syndrome (extra chromosome 13). If your baby has 
an increased risk for these chromosome differences, one of the antenatal screening midwives will 
have already contacted you before sending you this leaflet. 
Studies have also shown that low PAPP-A may also be associated with small babies, early 
deliveries and pre-eclampsia (high blood pressure and protein in your urine). An unborn baby is 
small if, at that stage of pregnancy, his or her size or estimated weight on scan is in the 
lowest 10% of babies. This means the smallest ten out of every 100 babies. Because of this, 
national guidelines suggest that extra scans should be considered to check the growth of babies 
when a low PAPP-A level has been found.  
 
What would being small mean for my baby? 
If your baby is small but healthy, he or she is not at increased risk of complications. If your baby 
is growth restricted, there is an increased risk of stillbirth (the baby dying in the womb). The 
extra scans help us to identify those babies that are small and allow us to put in place extra 
monitoring as required and consider earlier delivery.  
 
 
When will I have the extra scans?  
We will ask you to come to the antenatal clinic after your 20-week anomaly scan to discuss the 
low PAPP-A result and make a personalised plan. 
At 24 weeks we will measure the blood flow to the uterus and check the growth of the baby. 
We will then check your baby’s growth, your baby’s fluid levels and the blood flow in the 
placenta at least every 4 weeks until delivery.  
When we see you will depend on your individual circumstances and be tailored to your specific 
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needs. All women and their babies will have a personalised plan made with the doctors looking 
after them. 
Sometimes you will be asked to attend our specialist growth clinic this is nothing to worry about. 
 
Is there anything I can do help my baby to grow well?  
If you smoke, it is extremely important that you stop. Smoking can affect the placenta and the 
baby’s growth. Your midwife can refer you for help to stop smoking. 
 
Who can I speak to if I need further information?  
You are welcome to phone one of the antenatal screening midwives if you have any queries or 
concerns. Receiving the news that you have low PAPP-A levels may cause anxiety but please be 
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